Donna M. Weber, M.D.

Peer-Reviewed Articles

1. Chohan, KL, Weber, DM, Feng, L, Wang, LM, Neelapu, SS, Olsem, J, Johnson, RJ, Morales de Partovi, C, Orlowski, R, Thomas, SK. Phase I study of pomalidomide in relapsed or refractory Waldenström macroglobulinaemia. British Journal of Haematology 207(1):244-248, 2025. e-Pub 2025. PMID: 40361301.
2. Saha S, Rehman L, Rehman A, Darbaniyan F, Weber DM, Becnel M, Gaballa MR, Thomas SK, Lee HC, Chang CC, Arora R, Menges M, Corallo S, Davila ML, Locke FL, Tanner MR, Neelapu SS, Shpall EJ, Flowers CR, Orlowski RZ, Jenq RR, Jain MD, Peterson C, Hansen DK, Saini NY, Patel KK. Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel. Blood Adv 9(14):3429-3440, 2025. e-Pub 2025. PMID: 40198765.
3. Moreno Rueda, LY, Wang, H, Akagi, K, Dang, M, Vora, A, Qin, L, Lee, HC, Patel, K, Lin, P, Mery, D, Zhan, F, Shaughnessy, JD, Yi, Q, Song, Y, Jiang, B, Gillison, M, Thomas, SK, Weber, DM, Diao, L, Wang, J, Kuiatse, I, Manasanch, EE, Symer, DE, Orlowski, R. Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targets. Cell Reports Medicine 6(2), 2025. e-Pub 2025. PMID: 39855192.
4. Pasvolsky, O, Ghanem, S, Milton, D, Rauf, M, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Aljawai, YM, Khan, HN, Kebriaei, P, Lee, HC, Patel, K, Thomas, SK, Weber, DM, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH. Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant. Blood cancer journal 14(1), 2024. e-Pub 2024. PMID: 38199987.
5. Pasvolsky O, Pasyar S, Bassett RL, Khan HN, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation. Cancer 130(9):1663-1672, 2024. e-Pub 2023. PMID: 38127583.
6. Alzahrani, K, Pasvolsky, O, Wang, Z, Milton, D, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Lee, HC, Patel, K, Manasanch, EE, Kebriaei, P, Thomas, SK, Weber, DM, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH. Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation. British Journal of Haematology 204(5):1944-1952, 2024. e-Pub 2024. PMID: 38448009.
7. Pasvolsky O, Ghanem S, Milton DR, Masood A, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma. Transplant Cell Ther 29(12):757-762, 2023. e-Pub 2023. PMID: 37673125.
8. Pasvolsky O, Milton DR, Masood A, Sami SS, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Saeed A, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience. Am J Hematol 98(10):1571-1578, 2023. e-Pub 2023. PMID: 37461327.
9. Pasvolsky O, Marcoux C, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Tewari P, Crawford-Suber L, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Outcomes of young adults (aged = 40 years) with newly diagnosed multiple myeloma after up-front autologous stem cell transplant. Br J Haematol 202(4):866-873, 2023. e-Pub 2023. PMID: 37376789.
10. Dang M, Wang R, Lee HC, Patel KK, Becnel MR, Han G, Thomas SK, Hao D, Chu Y, Weber DM, Lin P, Lutter-Berka Z, Berrios Nolasco DA, Huang M, Bansal H, Song X, Zhang J, Futreal A, Moreno Rueda LY, Symer DE, Green MR, Rojas Hernandez CM, Kroll M, Afshar-Khargan V, Ndacayisaba LJ, Kuhn P, Neelapu SS, Orlowski RZ, Wang L, Manasanch EE. Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease. Cancer Cell 41(6):1032-1047.e4, 2023. e-Pub 2023. PMID: 37311413.
11. Pasvolsky O, Milton DR, Rauf M, Ghanem S, Masood A, Mohamedi AH, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Rezvani K, Champlin R, Shpall EJ, Lin P, Qazilbash MH. Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients. Blood Cancer J 13(1):68, 2023. e-Pub 2023. PMID: 37137874.
12. Pasvolsky O, Saliba RM, Masood A, Mohamedi AH, Tanner MR, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of gender on outcomes of patients with multiple myeloma undergoing autologous Haematopoietic stem cell transplant. Br J Haematol 201(4):e37-e41, 2023. e-Pub 2023. PMID: 36916461.
13. Afrough A, Alsfeld LC, Milton DR, Delgado R, Popat UR, Nieto Y, Kebriaei P, Oran B, Saini N, Srour S, Hosing C, Cheema FH, Ahmed S, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Weber DM, Orlowski RZ, Pinnix CC, Dabaja BS, Thomas SK, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q. Long-term outcomes of allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma. Transplant Cell Ther 29(4):264.e1-264.e9, 2023. e-Pub 2023. PMID: 35605883.
14. Pasvolsky O, Gaballa MR, Milton DR, Masood A, Sami SS, Tanner MR, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Tang G, Lin P, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience: Transplant in t(4;14) MM. Transplant Cell Ther 29(4):260.e1-260.e6, 2023. e-Pub 2023. PMID: 36646323.
15. Shank BR, Primeaux B, Yeung EK, Horowitz SB, Lee IY, Roccograndi L, Feng L, Kaufman GP, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Weber DM, Becnel MR, Thomas SK. Hyperfractionated Cyclophosphamide and Dexamethasone Alone or in Combination with Daratumumab and/or Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma: A Single-Center Retrospective Analysis. Clin Lymphoma Myeloma Leuk 23(4):279-290, 2023. e-Pub 2023. PMID: 36797154.
16. Damron, EP, Qazilbash, MH, Fang, PQ, Wu, SY, Dabaja, BS, Rondon, G, Hosing, C, Champlin, RE, Bashir, Q, Shpall, E, Knafl, M, Lee, HC, Manasanch, EE, Patel, K, Thomas, SK, Orlowski, R, Weber, DM, Pinnix, CC, Gunther, J. Radiation Therapy Can Be Safely Incorporated into Pretransplantation Treatment Regimens for Patients with Multiple Myeloma. Transplantation and Cellular Therapy 29(1):37.e1-37.e7, 2023. e-Pub 2023. PMID: 37753818.
17. Pasvolsky O, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour S, Tang G, Saini N, Ramdial J, Masood A, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Lenalidomide-Based Maintenance After Autologous Hematopoietic Stem Cell Transplant for Patients with High-Risk Multiple Myeloma. Transplant Cell Ther 28(11):752.e1-752.e6, 2022. e-Pub 2022. PMID: 35940528.
18. Pasvolsky, O, Milton, D, Rauf, M, Ghanem, S, Masood, A, Mohamedi, A, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Ramdial, JL, Nieto, Y, Tang, G, Lee, HC, Patel, K, Kebriaei, P, Thomas, SK, Weber, DM, Orlowski, R, Shpall, E, Champlin, RE, Lin, P, Qazilbash, MH. MM-403 Impact of Clonal Plasma Cells in Autografts on the Outcome of High-Risk Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplant. Clinical Lymphoma, Myeloma and Leukemia 22:S421-S422, 2022. e-Pub 2022. PMID: 36164172.
19. Kalariya N, Ferreri C, Dillard C, Hawkins M, Manasanch E, Lee H, Weber D, Thomas S, Steiner R, Hosing C, Qazilbash M, Popat U, Orlowski R, Hildebrandt M, Patel K. CT-511 Clinical Characteristics and Response Outcomes in Older Multiple Myeloma Patients Who Received Idecabtagene Vicleucel: A Single Center Study. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S446, 2022. e-Pub 2022. PMID: 36164224.
20. Mohan M, Becnel MR, Shah UA, Dong H, Gundarlapalli S, Peterson T, Orozco JS, Horowitz S, Chhabra S, Dhakal B, Thanendrarajan S, Radhakrishnan SV, Al Hadidi S, Tan C, Mailankody S, Hultcrantz M, Korde N, Hassoun H, Lesokhin AM, Thomas SK, Patel KK, Manasanch EE, Weber DM, Szabo A, Kaufman GP, Lee HC, Zangari M, van Rhee F, Usmani SZ, D'Souza A, Orlowski RZ, Schinke C. Clinical Efficacy of Sequencing CD38 targeting monoclonal antibodies in Relapsed Refractory Multiple Myeloma: A multi-institutional experience. Am J Hematol 97(7):E276-E280, 2022. e-Pub 2022. PMID: 35472167.
21. Gaballa MR, Ma J, Rauf M, Bassett R, Pasvolsky O, Tanner MR, Bashir Q, Srour SA, Saini N, Ramdial J, Nieto Y, Murphy R, Rezvani K, Tang G, Lin P, Lee HC, Patel KK, Ullah MR, Kaufman GP, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Shpall EJ, Champlin RE, Orlowski RZ, Qazilbash MH. KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma. Bone Marrow Transplant 57(7):1142-1149, 2022. e-Pub 2022. PMID: 35523847.
22. Afrough A, Pasvolsky O, Ma J, Srour S, Bashir Q, Saini N, Hosing C, Popat UR, Kebriaei P, Delgado R, Ullah MR, Murphy R, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of Induction with VCD vs. VRD on the Outcome of Patients with Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation. Transplant Cell Ther 28(6):307.e1-307.e8, 2022. e-Pub 2022. PMID: 35331973.
23. Patel KK, Shah JJ, Feng L, Lee HC, Manasanch EM, Olsem J, Morphey A, Huo XJ, Thomas SK, Bashir Q, Qazilbash MH, Weber DM, Orlowski RZ. Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Post-transplant Myeloma Patients. Clin Cancer Res 28(7):1277-1284, 2022. e-Pub 2022. PMID: 34992070.
24. Gaballa MR, Ma J, Tanner MR, Al-Juhaishi T, Bashir Q, Srour SA, Saini NY, Ramdial JL, Nieto Y, Murphy R, Rezvani K, Tang G, Lee HC, Patel KK, Kaufman GP, Manasanch EE, Ullah MR, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. Leuk Lymphoma 63(3):1-12, 2022. e-Pub 2022. PMID: 34686083.
25. Callander NS, Baljevic M, Adekola K, Anderson LD, Campagnaro E, Castillo JJ, Costello C, Devarakonda S, Elsedawy N, Faiman M, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Liedtke M, Martin T, Omel J, Sborov D, Shain K, Stockerl-Goldstein K, Weber D, Berardi RA, Kumar R, Kumar SK. NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022. J Natl Compr Canc Netw 20(1):8-19, 2022. e-Pub 2022. PMID: 34991075.
26. Patel R, Ma J, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Daher M, Mehta R, Srour S, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Shpall ES, Champlin RE, Saini N, Qazilbash MH. Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity-score matched analysis. Am J Hematol 96((12)):E455-E457, 2021. e-Pub 2021. PMID: 34559916.
27. Srour SA, Milton DR, Bashir Q, Nieto Y, Saini N, Daher M, Ramdial J, Im J, Hosing C, Delgado R, Manasanch E, Lee HC, Thomas S, Kaufman G, Patel K, Popat U, Weber D, Orlowski R, Shpall E, Champlin RE, Qazilbash MH. Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma. Haematologica 106(12):3211-3214, 2021. e-Pub 2021. PMID: 34407606.
28. Kunacheewa C, Feng L, Manasanch EE, Bashir Q, Patel KK, Mehta R, Kaufman GP, Srour S, Saini N, Iyer SP, Thomas SK, Weber DM, Orlowski RZ, Qazilbash MH, Lee HC. Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy. Br J Haematol 193(3):e23-e26, 2021. e-Pub 2021. PMID: 33748943.
29. Wang Y, Gali VL, Xu-Monette ZY, Sano D, Thomas SK, Weber DM, Zhu F, Fang X, Deng M, Zhang M, Hagemeister FB, Li Y, Orlowski RZ, Lee HC, Young KH. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia. Neoplasia 23(4):361-374, 2021. e-Pub 2021. PMID: 33735664.
30. Manasanch EE, Kunacheewa C, Claussen CM, Lee HC, Thomas SK, Gunther J, Pinnix CC, Dabaja BS, Amini B, Alexanian R, Orlowski RZ, Dong W, Feng L, Weber DM. Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow up. Blood Cancer J 11(2):17, 2021. e-Pub 2021. PMID: 33563896.
31. Hao S, Lu X, Gong Z, Bassett RL, Hu S, Konoplev SN, Tang G, Li S, Xu J, Khanlari M, Lee HC, Manasanch EE, Weber DM, Orlowski RZ, Jeffrey Medeiros L, Lin P. The survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma. Mod Pathol 34(2):327-335, 2021. e-Pub 2021. PMID: 32908255.
32. Manasanch EE, Berrios D, Fountain E, Claussen CM, Chuang T, Kaufman G, Amini B, Bashir Q, Nieto Y, Qazilbash M, Patel K, Thomas SK, Weber DM, Berkova Z, Toruner G, Lin P, Feng L, Lee HC, Orlowski RZ, Kunacheewa C. Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapies. Br J Haematol 192(4):e115-e120, 2021. e-Pub 2021. PMID: 33486754.
33. Manasanch EE, Mulanovich V, Manzano JG, Gaeta MS, Becnel M, Kaufman GP, Lee HC, Amini B, Thomas SK, Iyer SP, Weber DM, Berkova Z, Flowers CR, Orlowski RZ, Patel KK. SARS-CoV-2 in multiple myeloma: initial observation and management. Leuk Lymphoma 61(11):2763-2766, 2020. e-Pub 2020. PMID: 33167721.
34. Saini N, Bashir Q, Milton DR, Tang G, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Mehta R, Srour S, Khouri IF, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. Blood Adv 4(19):4834-4837, 2020. e-Pub 2020. PMID: 33027527.
35. Figgins B, Primeaux B, Shank BR, Chen SE, Weber DM, Lu H. Cyclophosphamide desensitization in patients with severe hypersensitivity reactions to bendamustine. J Oncol Pharm Pract 26(4):1078155219867127, 2020. e-Pub 2020. PMID: 31433727.
36. Cordas Dos Santos DM, Saliba RM, Patel R, Bashir Q, Saini N, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Popat U, Ahmed H, Lee HC, Manasanch EE, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 26(6):1077-1083, 2020. e-Pub 2020. PMID: 31786242.
37. Kunacheewa C, Lee HC, Patel K, Thomas S, Amini B, Srour S, Bashir Q, Nieto Y, Qazilbash MH, Weber DM, Feng L, Orlowski RZ, Lin P, Manasanch EE. Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study. Clin Lymphoma Myeloma Leuk 20(5):e221-e238, 2020. e-Pub 2020. PMID: 32037287.
38. Varma A, Sui D, Milton DR, Tang G, Saini N, Hasan O, Mukherjee A, Joseph JJ, Bashir Q, Rondon G, Srour S, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Mehta R, Khouri IF, Ahmed H, Iyer S, Weber DM, Thomas SK, Manasanch E, Lee HC, Patel K, Ciurea SO, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. Biol Blood Marrow Transplant 26(4):665-671, 2020. e-Pub 2020. PMID: 31881283.
39. Lee HC, Shah JJ, Feng L, Morphey A, Johnson RJ, Wesson ET, Wang ML, Alexanian R, Thomas SK, Orlowski RZ, Weber DM. A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Am J Hematol 94(12):E319-E322, 2019. e-Pub 2019. PMID: 31489991.
40. Saini N, Ma J, Milton DR, Patel R, Varma A, Bashir Q, Delgado R, Mukherjee A, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Tang G, Mehta R, Srour S, Khouri IF, Iyer S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis. Clin Cancer Res 25(22):6781-6787, 2019. e-Pub 2019. PMID: 31481508.
41. Lee HC, Shah JJ, Feng L, Manasanch EE, Lu R, Morphey A, Crumpton B, Patel KK, Wang ML, Alexanian R, Thomas SK, Weber DM, Orlowski RZ. A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma. Blood Cancer J 9(10):80, 2019. e-Pub 2019. PMID: 31575851.
42. Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Mukherjee A, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemia. Ann Hematol 98(9):2233-2235, 2019. e-Pub 2019. PMID: 31243571.
43. Tabchi S, Nair R, Kunacheewa C, Patel KK, Lee HC, Thomas SK, Amini B, Ahmed S, Mehta RS, Bashir Q, Qazilbash MH, Weber DM, Orlowski RZ, Alexanian R, Feng L, Manasanch EE. Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia. Clin Lymphoma Myeloma Leuk 19(9):560-569, 2019. e-Pub 2019. PMID: 31201134.
44. Manasanch EE, Han G, Mathur R, Qing Y, Zhang Z, Lee H, Weber DM, Amini B, Berkova Z, Eterovic K, Zhang S, Zhang J, Song X, Mao X, Morgan M, Feng L, Baladandayuthapani V, Futreal A, Wang L, Neelapu SS, Orlowski RZ. A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis. Blood Adv 3(15):2400-2408, 2019. e-Pub 2019. PMID: 31405950.
45. Elhammali A, Milgrom SA, Amini B, Gunther JR, Yoder A, Ludmir EB, Moon B, Weber DM, Thomas SK, Garg N, Manasanch EE, Patel KK, Orlowski RZ, Lee HC, Bird JE, Satcher R, Lin P, Pinnix CC, Dabaja BS. Postoperative Radiotherapy for Multiple Myeloma of Long Bones: Should the Entire Rod Be Treated?. Clin Lymphoma Myeloma Leuk 19(8):e465-e469, 2019. e-Pub 2019. PMID: 31133526.
46. Gowda L, Shah M, Badar I, Bashir Q, Shah N, Patel K, Kanagal-Shamanna R, Mehta R, Weber DM, Lee HC, Manasanch EE, Shah A, Thomas SK, Parmar S, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MH. Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs. Bone Marrow Transplant 54(7):1089-1093, 2019. e-Pub 2019. PMID: 30446740.
47. Bashir Q, Thall PF, Milton DR, Fox PS, Kawedia JD, Kebriaei P, Shah N, Patel K, Andersson BS, Nieto YL, Valdez BC, Parmar S, Rondon G, Delgado R, Hosing C, Popat UR, Oran B, Ciurea SO, Lin P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Williams LA, Champlin RE, Qazilbash MH. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Haematol 6(5):e266-e275, 2019. e-Pub 2019. PMID: 30910541.
48. Chaudhry M, Steiner R, Claussen C, Patel K, Lee H, Weber D, Thomas S, Feng C, Amini B, Orlowski R, Feng L, Manasanch EE. Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenström's macroglobulinemia. Leuk Lymphoma 60(4):964-970, 2019. e-Pub 2019. PMID: 30227761.
49. Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome. Am J Hematol 94(3):E72-E74, 2019. e-Pub 2019. PMID: 30548467.
50. Hu B, Thall P, Milton DR, Sasaki K, Bashir Q, Shah N, Patel K, Popat U, Hosing C, Nieto Y, Lin P, Delgado R, Jorgensen J, Manasanch E, Weber D, Thomas S, Orlowski RZ, Champlin R, Qazilbash MH. High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. Leuk Lymphoma 60(2):442-452, 2019. e-Pub 2019. PMID: 30032678.
51. Saini NY, Patel R, Varma A, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Melphalan-based autologous transplant in octogenarian multiple myeloma patients. Am J Hematol 94(1):E2-E5, 2019. e-Pub 2019. PMID: 30300461.
52. Manasanch EE, Shah JJ, Lee HC, Weber DM, Thomas SK, Amini B, Olsem J, Crumpton B, Morphey A, Berkova Z, Feng L, Orlowski RZ. Phase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma. Haematologica 105(5):e242-e245, 2019. e-Pub 2019. PMID: 31413094.
53. Buege MJ, Do B, Lee HC, Weber DM, Horowitz SB, Feng L, Qing Y, Shank BR. Corrected calcium versus ionized calcium measurements for identifying hypercalcemia in patients with multiple myeloma. Cancer Treat Res Commun 21:100159, 2019. e-Pub 2019. PMID: 31521048.
54. Manasanch EE, Shah JJ, Lee HC, Weber DM, Thomas SK, Amini B, Feng L, Berkova Z, Hildebrandt M, Orlowski RZ. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial. Lancet Haematol 5(12):e628-e640, 2018. e-Pub 2018. PMID: 30501870.
55. Afrough A, Saliba RM, Hamdi A, Honhar M, Varma A, Cornelison AM, Rondon G, Parmar S, Shah ND, Bashir Q, Hosing C, Popat U, Weber DM, Thomas S, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 24(11):2197-2203, 2018. e-Pub 2018. PMID: 30016656.
56. Mohyuddin GR, Faisal MS, Badar T, Shah N, Bashir Q, Patel KK, Hosing C, Popat UR, Rondon G, Delgado R, Shah JJ, Weber DM, Thomas SK, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH. A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center. Leuk Lymphoma 59(2):1-4, 2018. e-Pub 2018. PMID: 28673185.
57. Hao S, Lin P, Medeiros LJ, Fang L, Carballo-Zarate AA, Konoplev SN, Sargent RL, Weber DM, Thomas SK, Manasanch EE, Orlowski RZ, Lu X. Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion. Mod Pathol 30(10):1378-1386, 2017. e-Pub 2017. PMID: 28664940.
58. Purushothaman A, Bandari SK, Chandrashekar DS, Jones RJ, Lee HC, Weber DM, Orlowski RZ. Chondroitin sulfate proteoglycan serglycin influences protein cargo loading and functions of tumor-derived exosomes. Oncotarget 8(43):73723-73732, 2017. e-Pub 2017. PMID: 29088739.
59. Baljevic M, Zaman S, Baladandayuthapani V, Lin YH, de Partovi CM, Berkova Z, Amini B, Thomas SK, Shah JJ, Weber DM, Fu M, Cleeland CS, Wang XS, Stellrecht CM, Davis RE, Gandhi V, Orlowski RZ. Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma. Ann Hematol 96(6):977-985, 2017. e-Pub 2017. PMID: 28337527.
60. Carballo-Zarate AA, Medeiros LJ, Fang L, Shah JJ, Weber DM, Thomas SK, Manasanch EE, Hao S, Shen Q, Orlowski RZ, Lin P, Lu X. Additional-structural-chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experience. Mod Pathol 30(6):843-853, 2017. e-Pub 2017. PMID: 28281554.
61. Lee HC, Weber DM. Advances and practical use of monoclonal antibodies in multiple myeloma therapy. Hematology Am Soc Hematol Educ Program 2016(1):512-520, 2016. e-Pub 2016. PMID: 27913523.
62. Jones RJ, Iempridee T, Wang X, Lee HC, Mertz JE, Kenney SC, Lin HC, Baladandayuthapani V, Dawson CW, Shah JJ, Weber DM, Orlowski RZ. Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein-Barr Virus Lytic Cycle Through Phosphoinositide 3-kinase Signaling and Ikaros Expression. Clin Cancer Res 22(19):4901-4912, 2016. e-Pub 2016. PMID: 27297582.
63. Badar T, Cornelison AM, Shah ND, Bashir Q, Parmar S, Patel K, Hosing C, Popat U, Weber DM, Thomas SK, Shah JJ, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients with Systemic Light chain (AL) Amyloidosis with Concurrent Renal and Cardiac Involvement. Eur J Haematol 97(4):342-7, 2016. e-Pub 2016. PMID: 26773409.
64. Zhang XD, Baladandayuthapani V, Lin H, Mulligan G, Li B, Esseltine DL, Qi L, Xu J, Hunziker W, Barlogie B, Usmani SZ, Zhang Q, Crowley J, Hoering A, Shah JJ, Weber DM, Manasanch EE, Thomas SK, Li BZ, Wang HH, Zhang J, Kuiatse I, Tang JL, Wang H, He J, Yang J, Milan E, Cenci S, Ma WC, Wang ZQ, Davis RE, Yang L, Orlowski RZ. Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling. Cancer Cell 29(5):639-52, 2016. e-Pub 2016. PMID: 27132469.
65. Cao X, Medeiros LJ, Xia Y, Wang X, Thomas SK, Loghavi S, Li X, Shah JJ, Gustafson SA, Weber DM, Miranda RN, Xu-Monette ZY, Orlowski RZ, Young KH. Clinicopathologic Features and Outcomes of Lymphoplasmacytic Lymphoma Patients with Monoclonal IgG or IgA Paraprotein Expression. Leuk Lymphoma 57(5):1-27, 2016. e-Pub 2016. PMID: 26421453.
66. Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R. NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016. J Natl Compr Canc Netw 14(4):389-400, 2016. e-Pub 2016. PMID: 27059188.
67. Kanagal-Shamanna R, Xu-Monette ZY, Miranda RN, Dogan A, Zou D, Luthra R, Weber DM, O'Malley DP, Jorgensen JL, Khoury JD, Bueso-Ramos CE, Orlowski RZ, Medeiros LJ, Young KH. Crystal-Storing Histiocytosis: A Clinicopathologic Study of 13 Cases. Histopathology 68(4):482-91, 2016. e-Pub 2016. PMID: 26118455.
68. Arentsen A, Welsh D, Jones M, Weber D, Taylor S, Kuperstein J, Rayens MK, Salt E. Student Perception of Improvement in Communication and Value in 2 Interprofessional Education Delivery Formats. Nurse Educ 41(2):90-2, 2016. e-Pub 2016. PMID: 26237007.
69. Shah JJ, Feng L, Thomas SK, Berkova Z, Weber DM, Wang M, Qazilbash MH, Champlin RE, Mendoza TR, Cleeland C, Orlowski RZ. Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial. Blood Cancer J 6:e396, 2016. e-Pub 2016. PMID: 26871714.
70. Jacobs RW, Saliba RM, Sasaki K, Farhan S, Armas A, Shah ND, Bashir Q, Qureshi S, Rondon G, Hosing C, Popat U, Parmar S, Shah JJ, Wang M, Weber DM, Thomas SK, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk 16(1):36-42, 2016. e-Pub 2016. PMID: 26702475.
71. Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Singhal S, Smith C, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R. Multiple Myeloma, Version 2.2016. J Natl Compr Canc Netw 13(11):1398-435, 2015. e-Pub 2015. PMID: 26553768.
72. Abudayyeh A, Truong LD, Beck LH, Weber DM, Rezvani K, Abdelrahim M. Membranous nephropathy in autologous hematopoietic stem cell transplant: autologous graft-versus-host disease or autoimmunity induction?. Clin Kidney J 8(4):440-4, 2015. e-Pub 2015. PMID: 26251713.
73. Kuiatse I, Baladandayuthapani V, Lin HY, Thomas SK, Bjorklund CC, Weber DM, Wang M, Shah JJ, Zhang XD, Jones RJ, Ansell SM, Yang G, Treon SP, Orlowski RZ. Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy Against Waldenström's Macroglobulinemia. Clin Cancer Res 21(11):2538-45, 2015. e-Pub 2015. PMID: 25748087.
74. Kongtim P, Qazilbash MH, Shah JJ, Hamdi A, Shah N, Bashir Q, Wang M, Champlin R, Manasanch EE, Weber D, Orlowski RZ, Parmar S. High-dose therapy with auto-SCT is feasible in high-risk cardiac amyloidosis. Bone Marrow Transplant 50(5):668-72, 2015. e-Pub 2015. PMID: 25730192.
75. Cao X, Ye Q, Orlowski RZ, Wang X, Loghavi S, Tu M, Thomas SK, Shan J, Li S, Qazilbash M, Yin CC, Weber D, Miranda RN, Xu-Monette ZY, Medeiros LJ, Young KH. Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. J Hematol Oncol 8(1):74, 2015. e-Pub 2015. PMID: 26104577.
76. Liu Z, Xu J, He J, Zheng Y, Li H, Lu Y, Qian J, Lin P, Weber DM, Yang J, Yi Q. A critical role of autocrine sonic hedgehog signaling in human CD138+ myeloma cell survival and drug resistance. Blood 124(13):2061-71, 2014. e-Pub 2014. PMID: 25049282.
77. Wuu A, Bangert SD, Weber DM, Hymes SR. Primary cutaneous plasmacytoma. Cutis 93(6):E19-21, 2014. e-Pub 2014. PMID: 24999652.
78. Bjorklund CC, Baladandayuthapani V, Lin HY, Jones RJ, Kuiatse I, Wang H, Yang J, Shah JJ, Thomas SK, Wang M, Weber DM, Orlowski RZ. Evidence of a Role for CD44 and Cell Adhesion in Mediating Resistance to Lenalidomide in Multiple Myeloma: Therapeutic Implications. Leukemia 28(2):373-83, 2014. e-Pub 2014. PMID: 23760401.
79. Cardoso RC, Gerngross PJ, Hofstede TM, Weber DM, Chambers MS. The multiple oral presentations of multiple myeloma. Support Care Cancer 22(1):259-267, 2014. e-Pub 2014. PMID: 24048519.
80. Patel K, Nusrat M, Shah N, Bashir Q, Parmar S, Shah J, Thomas S, Weber D, Orlowski RZ, Champlin R, Qazilbash MH. Durable responses with autologous hematopoietic SCT in patients with POEMS syndrome. Bone Marrow Transplant 49(3):465-6, 2014. e-Pub 2014. PMID: 24419515.
81. Garcia MK, Cohen L, Guo Y, Zhou Y, You B, Chiang J, Orlowski RZ, Weber D, Shah J, Alexanian R, Thomas S, Romaguera J, Zhang L, Badillo M, Chen Y, Wei Q, Lee R, Delasalle K, Green V, Wang M. Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study. J Hematol Oncol 7(1):41, 2014. e-Pub 2014. PMID: 24886772.
82. Siegel DS, Richardson P, Dimopoulos M, Moreau P, Mitsiades C, Weber D, Houp J, Gause C, Vuocolo S, Eid J, Graef T, Anderson KC. Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood Cancer J 4:e182, 2014. e-Pub 2014. PMID: 24562384.
83. Alexanian R, Wang M, Delasalle K, Wang S, Qazilbash M, Handy B, Weber D. Value of novel agents and intensive therapy for patients with multiple myeloma. Bone Marrow Transplant. e-Pub 2013. PMID: 24317125.
84. Richardson PG, Schlossman RL, Alsina M, Weber DM, Coutre SE, Gasparetto C, Mukhopadhyay S, Ondovik MS, Khan M, Paley CS, Lonial S. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood 122(14):2331-2337, 2013. e-Pub 2013. PMID: 23950178.
85. Valdez BC, Wang G, Murray D, Nieto Y, Li Y, Shah J, Turturro F, Wang M, Weber DM, Champlin RE, Qazilbash MH, Andersson BS. Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: Relevance of p53 and its clinical implications. Exp Hematol 41(8):719-30, 2013. e-Pub 2013. PMID: 23648290.
86. Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C, Hernandez-Illizaliturri F, Huff CA, Kassim A, Krishnan AY, Liedtke M, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Yunus F, Shead DA, Kumar R. Multiple myeloma, version 1.2013. J Natl Compr Canc Netw 11(1):11-7, 2013. e-Pub 2013. PMID: 23307977.
87. Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, Davis RE, Lin P, Wang H, Madden TL, Wei C, Baladandayuthapani V, Wang M, Thomas SK, Shah JJ, Weber DM, Orlowski RZ. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in pre-clinical models of multiple myeloma. Blood 120(16):3260-70, 2012. e-Pub 2012. PMID: 22932796.
88. Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C, Hernandez-Ilizaliturri F, Huff CA, Kassim A, Krishnan AY, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F, Kumar R, Shead DA, NCCN. Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2013. J Natl Compr Canc Netw 10(10):1211-1219, 2012. e-Pub 2012. PMID: 23054875.
89. Weber DM, Graef T, Hussein M, Sobecks RM, Schiller GJ, Lupinacci L, Hardwick JS, Jagannath S. Phase I Trial of Vorinostat Combined With Bortezomib for the Treatment of Relapsing and/or Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk 12(5):319-24, 2012. e-Pub 2012. PMID: 23040438.
90. Chanan-Khan AA, Lonial S, Weber D, Borrello I, Foà R, Hellmann A, Dimopoulos M, Swern AS, Knight R. Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients 65 years old with relapsed or refractory multiple myeloma. Int J Hematol 96(2):254-62, 2012. e-Pub 2012. PMID: 22752567.
91. Sweeney SA, Kumar VA, Tayar J, Weber DM, Safdar A, Alonso C, Hymes S. Case 181: synovitis acne pustulosis hyperostosis osteitis (SAPHO) syndrome. Radiology 263(2):613-7, 2012. e-Pub 2012. PMID: 22517965.
92. Dimopoulos MA, Richardson PG, Brandenburg N, Yu Z, Weber DM, Niesvizky R, Morgan GJ. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood 119(12):2764-2767, 2012. e-Pub 2012. PMID: 22323483.
93. Bashir Q, Khan H, Orlowski RZ, Amjad AI, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Thomas SK, Shah JJ, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol 87(3):272-6, 2012. e-Pub 2012. PMID: 22231283.
94. Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Orlowski RZ, Thomas SK, Shah J, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Feasibility of autologous hematopoietic stem cell transplant in patients aged =70 years with multiple myeloma. Leuk Lymphoma 53(1):118-22, 2012. e-Pub 2012. PMID: 21780997.
95. Sweeney SA, Kumar VA, Tayar J, Weber DM, Safdar A, Alonso C, Hymes S. Case 181. Radiology 262(1):361-3, 2012. e-Pub 2012. PMID: 22190660.
96. Zheng Y, Yang J, Qian J, Qiu P, Hanabuchi S, Lu Y, Wang Z, Liu Z, Li H, He J, Lin P, Weber D, Davis RE, Kwak L, Cai Z, Yi Q. PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma. Leukemia 27(3):702-10, 2012. e-Pub 2012. PMID: 22996336.
97. Alexanian R, Delasalle K, Wang M, Thomas S, Weber D. Curability of multiple myeloma. Bone Marrow Res 2012:916479, 2012. e-Pub 2012. PMID: 22675638.
98. Reed V, Shah J, Medeiros LJ, Ha CS, Mazloom A, Weber DM, Arzu IY, Orlowski RZ, Thomas SK, Shihadeh F, Alexanian R, Dabaja BS. Solitary plasmacytomas: Outcome and prognostic factors after definitive radiation therapy. Cancer 117(19):4468-74, 2011. e-Pub 2011. PMID: 21437886.
99. Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, Leleu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Bladé J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG, Working Group OBOTIM, Working Group IM, Abildgaard N, Abonour R, Alexanian R, Alsina M, Anderson KC, Attal M, Avet-Loiseau H, Badros A, Baris D, Barlogie B, Bataille R, Beksaç M, Belch A, Ben-Yehuda D, Bensinger B, Leif Bergsagel P, Bird J, Bladé J, Boccadoro M, Cavo M, Chanan-Khan A, Ming Chen W, Child T, Chim J, Chng WJ, Comenzo R, Crowley J, Dalton W, Davies F, de Souza C, Delforge M, Dimopoulos M, Dispenzieri A, Drach J, Drake M, Durie BG, Einsele H, Facon T, Fantl D, Fermand JP, Fonseca R, Gahrton G, García-Sanz R, Gasparetto C, Gertz M, Gibson J, Giralt S, Goldschmidt H, Greipp P, Hajek R, Hardan I, Hari P, Harousseau JL, Hata H, Hattori Y, Heffner T, Ho J, Hungria V, Ida S, Jacobs P, Jagannath S, Johnsen H, Jian H, Joshua D, Jurczyszyn A, Kawano M, Kröger N, Kumar S, Kyle RA, Lacy M, Lahuerta JJ, Landgren O, Laubach J, Lee JH, Leleu X, Lentzsch S, Lokhorst H, Lonial S, Ludwig H, Maiolino A, Mateos M, Mehta J, Mellqvist UH, Merlini G, Mikhael J, Morales AR, Moreau P, Morgan G, Nari H, Munshi N, Niesvizky R, Nouel A, Novis Y, Orlowski R, Palumbo A, Pavlovsky S, Pilarski L, Powles R, Raje N, Vincent Rajkumar S, Reece D, Reiman T, Richardson PG, Roodman D, Rosiñol L, Miguel JS, Sezer O, Shah JJ, Shaughnessy J, Shimizu K, Shustik C, Siegel D, Singhal S, Sonneveld P, Spencer A, Stadtmauer E, Stewart K, Terpos E, Tosi P, Tricot G, Turesson I, Van Camp B, Van Ness B, Van Riet I, Broek IV, Vanderkerken K, Vescio R, Vesole D, Waage A, Wang M, Weber D, Westin J, Wheatley K, Zonder J. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia. e-Pub 2011. PMID: 21799510.
100. Ishak KJ, Caro JJ, Drayson MT, Dimopoulos M, Weber D, Augustson B, Child JA, Knight R, Iqbal G, Dunn J, Shearer A, Morgan G. Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myeloma. Value Health 14(5):672-8, 2011. e-Pub 2011. PMID: 21839405.
101. Hunsucker SA, Magarotto V, Kuhn DJ, Kornblau SM, Wang M, Weber DM, Thomas SK, Shah JJ, Voorhees PM, Xie H, Cornfeld M, Nemeth JA, Orlowski RZ. Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol 152(5):579-92, 2011. e-Pub 2011. PMID: 21241278.
102. San-Miguel JF, Dimopoulos MA, Stadtmauer EA, Rajkumar SV, Siegel D, Bravo ML, Olesnyckyj M, Knight RD, Zeldis JB, Harousseau JL, Weber DM. Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Clin Lymphoma Myeloma Leuk 11(1):38-43, 2011. e-Pub 2011. PMID: 21273172.
103. Harousseau JL, Dimopoulos MA, Wang M, Corso A, Chen C, Attal M, Spencer A, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. The quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica 10:1738-44, 2010. e-Pub 2010. PMID: 20460639.
104. Ma W, Wang M, Wang ZQ, Sun L, Graber D, Matthews J, Champlin R, Yi Q, Orlowski RZ, Kwak LW, Weber DM, Thomas SK, Shah J, Kornblau S, Davis RE. Effect of Long-term Storage in TRIzol on Microarray-Based Gene Expression Profiling. Cancer Epidemiol Biomarkers Prev 19(10):2445-52, 2010. e-Pub 2010. PMID: 20805315.
105. Dimopoulos M, Alegre A, Stadtmauer EA, Goldschmidt H, Zonder JA, de Castro CM, Masliak Z, Reece D, Olesnyckyj M, Yu Z, Weber DM. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer 116(16):3807-14, 2010. e-Pub 2010. PMID: 20564094.
106. Berenson JR, Anderson KC, Audell RA, Boccia RV, Coleman M, Dimopoulos MA, Drake MT, Fonseca R, Harousseau JL, Joshua D, Lonial S, Niesvizky R, Palumbo A, Roodman GD, San-Miguel JF, Singhal S, Weber DM, Zangari M, Wirtschafter E, Yellin O, Kyle RA. Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol 150(1):28-38, 2010. e-Pub 2010. PMID: 20507313.
107. Zangari M, Tricot G, Polavaram L, Zhan F, Finlayson A, Knight R, Fu T, Weber D, Dimopoulos MA, Niesvizky R, Fink L. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. J Clin Oncol 28(1):132-5, 2010. e-Pub 2010. PMID: 19901114.
108. Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA, Petrucci MT, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 23(11):2147-52, 2009. e-Pub 2009. PMID: 19626046.
109. Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Gasparetto C, Huff CA, Jagasia M, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Tricot G, Vose JM, Weber D, Yahalom J, Yunus F. NCCN clinical practice guidelines in oncology: multiple myeloma. J Natl Compr Canc Netw 7(9):908-42, 2009. e-Pub 2009. PMID: 19878637.
110. Parikh GC, Amjad AI, Saliba RM, Kazmi SM, Khan ZU, Lahoti A, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Popat U, Alousi AM, Champlin RE, Giralt SA, Qazilbash MH. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant 15(7):812-6, 2009. e-Pub 2009. PMID: 19539212.
111. Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, Shpall E, McMannis J, Körbling M, Alousi A, Andersson B, Nieto Y, Kebriaei P, Khouri I, de Lima M, Weber D, Thomas S, Wang M, Jones R, Champlin R, Giralt S. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 15(6):718-723, 2009. e-Pub 2009. PMID: 19450756.
112. Stadtmauer EA, Weber DM, Niesvizky R, Belch A, Prince MH, San Miguel JF, Facon T, Olesnyckyj M, Yu Z, Zeldis JB, Knight RD, Dimopoulos MA. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. Eur J Haematol 82(6):426-32, 2009. e-Pub 2009. PMID: 19302559.
113. Qazilbash MH, Saliba RM, Nieto Y, Parikh G, Pelosini M, Khan FB, Jones RB, Hosing C, Mendoza F, Weber DM, Wang M, Popat U, Alousi A, Anderlini P, Champlin RE, Giralt S. Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant 14(12):1401-7, 2008. e-Pub 2008. PMID: 19041063.
114. Wang M, Dimopoulos MA, Chen C, Cibeira MT, Attal M, Spencer A, Rajkumar SV, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 112(12):4445-4451, 2008. e-Pub 2008. PMID: 18799726.
115. Campagnaro E, Saliba R, Giralt S, Roden L, Mendoza F, Aleman A, Cleeland C, Weber D, Brown J, Anderson KO. Symptom burden after autologous stem cell transplantation for multiple myeloma. Cancer 1(112(7)):1617-1624, 2008. e-Pub 2008.
116. Anderson K, Kyle R, Rajkumar SV, Stewart K, Weber D, Richardson P. ASH/FDA Workshop on Clinical Endpoints in Multiple Myeloma. Leukemia 22((2)):231-239, 2008. e-Pub 2008.
117. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson P, San Miguel J, Barlogie B, Harousseau J, Zonder J, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig J, Vesole D, Blade J, Kyle R, Westin J, Weber D, Bringhen S, Niesvizky R, Waage A, Lonial S, Morgan G, Orlowski R, Shimzu K, Anderson K, Boccardoro M, Durie BG, Hussein MA. Prevention of thalidomide and lenalidomide associated thrombosis in myeloma. Leukemia 22((2)):414-423, 2008. e-Pub 2008.
118. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD, Study Investigators MM. Lenalidomide Plus Dexamethasone for Relapsed Multiple Myeloma in North America. N Engl Med 357((21)):2133-2142, 2007. e-Pub 2007.
119. Qazilbash MH, Saliba RM, Ahmed B, Parikh G, Mendoza F, Ashraf N, Hosing C, Flosser T, Weber DM, Wang M, Couriel DR, Popat U, Kebriaei P, Alousi AM, Anderlini P, Naeem RC, Champlin RE, Giralt SA. Deletion of the Short Arm of Chromosome 1 (del 1p) is a Strong Predictor of Poor Outcome in Myeloma Patients Undergoing an Autotransplant. Biol Blood Marrow Transplant 13(9):1066-72, 2007. e-Pub 2007. PMID: 17697969.
120. Anderson, KC, Alsina, M, Bensinger, W, Bermann, JS, Chanan-Khan, A, Comenzo, RL, DeCastro, CM, Djalbegovic, B, Farag, S, Huff, CA, Meredith, R, Schriber, J, Shrieve, D, Singhal, S, Smith, MR, Stocker/Goldstein, K, Vose, JM, Weber, D, Yahalom, J, Yunus, F. Multiple myeloma clinical practice guidelines in oncology. J. Natl Compr Canc Netw 5(2):118-47, 2007. e-Pub 2007.
121. Qazilbash MH, Saliba RM, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Flosser T, Couriel DR, De Lima M, Kebriaei P, Popat U, Alousi AM, Champlin RE, Giralt SA. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant 39(5):279-83, 2007. e-Pub 2007. PMID: 17262062.
122. Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Comenzo RL, De Castro CM, Djulbegovic B, Farag S, Huff CA, Meredith R, Schriber J, Shrieve D, Singhal S, Smith MR, Stockerl-Goldstein K, Vose JM, Weber D, Yahalom J, Yunus F. Multiple Myeloma. Clinical practice guidelines in oncology. National Comprehensive Cancer Network 5(2):118-47, 2007. e-Pub 2007.
123. Qazilbash MH, Saliba RM, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Flosser T, Couriel DR, De Lima M, Debriaci P, Popat U, Alousi AM, Champlin RE, Giralt SA. Autologous stem cell transplantation in safe and feasible in elderly patients with mulitple myeloma. Bone Marrow Transplantation 39:279-283, 2007. e-Pub 2007.
124. Christoforidou AV, Saliba RM, Williams P, Qazilbash M, Roden L, Aleman A, Weber D, Mendoza F, Podoloff D, Rrd W, Breitz H, Alexanian R, Giralt S. Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166) Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes. Biol Blood Marrow Transplant 13(5):543-9, 2007. e-Pub 2007.
125. Qazilbash MH, Saliba RM, Aleman A, Lei X, Weber D, Carrasco A, Champlin RE, Giralt SA. Risk Factors for Relapse After Complete Remission with High-dose Therapy for Multiple Myeloma. Leuk Lymphoma 47(7):1360-1364, 2006. e-Pub 2006.
126. Merzianu M, Jiang L, Lin P, Wang X, Weber DM, Vadhan-Raj S, Nguyen MH, Medeiros LI, Bueso-Ramos CE. Nuclear BCL-10 Expression is Common in Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia and does not correlate with p65 NF-kappaB Activation. Mod Pathol 19((7)):891-898, 2006. e-Pub 2006.
127. Merzianu M, Jiang L, Lin P, Wang X, Weber DM, Vadhan-Raj S, Nguyen MH, Medeiros LJ, Bueso-Ramos CE. Nuclear BCL-10 expression is common in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia and does not correlate with p65 NF-kappaB activation. Mod Pathol 19(7):891-8, 2006. e-Pub 2006. PMID: 16636680.
128. Donato M, Feasel A, Weber D, Prieto V, Giralt S, Champlin R. Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation. Blood 107:463-466, 2006. e-Pub 2006.
129. Amit-Vazina M, Shishodia S, Harris D, Van Q, Wang M, Weber D, Alexanian R, Talpaz M, Aggarwal BB, Estrov Z. Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells. Br J Cancer 93(1):70-80, 2005. e-Pub 2005. PMID: 15970928.
130. Wang M, Weber DM, Delasalle K, Alexanian R. Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma. Am J Hematol 79(3):194-7, 2005. e-Pub 2005. PMID: 15981221.
131. Dimopoulos MA, Alexanian R, Gika D, Anagnostopoulos A, Zervas C, Zomas A, Kyrtsonis MC, Anagnostopoulos N, Pangalis GA, Weber DM. Treatment of Waldenstrom's macroglobulinemia with rituximab: prognostic factors for response and progression. Leuk Lymphoma 45(10):2057-61, 2004. e-Pub 2004. PMID: 15370250.
132. Alexanian R, Weber D, Delasalle K, Handy B, Champlin R, Giralt S. Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma. Bone Marrow Transplant 34(3):229-34, 2004. e-Pub 2004. PMID: 15170166.
133. Anagnostopoulos A, Aleman A, Ayers G, Donato M, Champlin R, Weber D, Alexanian R, Giralt S. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma. Cancer 100(12):2607-12, 2004. e-Pub 2004. PMID: 15197803.
134. Bharti AC, Shishodia S, Reuben JM, Weber D, Alexanian R, Raj-Vadhan S, Estrov Z, Talpaz M, Aggarwal BB. Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 103(8):3175-84, 2004. e-Pub 2004. PMID: 15070700.
135. Donato ML, Aleman A, Champlin RE, Weber D, Alexanian R, Ippoliti CM, de Lima M, Anagnostopoulos A, Giralt S. High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma. Leuk Lymphoma 45(4):755-9, 2004. e-Pub 2004. PMID: 15160952.
136. Anagnostopoulos A, Aleman A, Yang Y, Donato M, Weber D, Champlin R, Smith T, Alexanian R, Giralt S. Outcomes of autologous stem cell transplantation in patients with multiple myeloma who received dexamethasone-based nonmyelosuppressive induction therapy. Bone Marrow Transplant 33(6):623-8, 2004. e-Pub 2004. PMID: 14730336.
137. Giralt S, Bensinger W, Goodman M, Podoloff D, Eary J, Wendt R, Alexanian R, Weber D, Maloney D, Holmberg L, Rajandran J, Breitz H, Ghalie R, Champlin R. 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials. Blood 102(7):2684-91, 2003. e-Pub 2003. PMID: 12730103.
138. Ahmed M, Giles F, Joe Y, Weber DM, Jilani I, Manshouri T, Giralt S, De Lima M, Keating M, Albitar M. Use of Plasma DNA in Detection of Loss Heterozygosity in Patients with Multiple Myeloma. Eur J Haematol 71((3)):174-8, 2003. e-Pub 2003.
139. Weber DM. Strategies in treating newly diagnosed or untreated multiple myeloma patients. From the Multiple Myeloma Research Foundation. Oncology (Williston Park) 17(6):765-7, 2003. e-Pub 2003. PMID: 12846120.
140. Anagnostopoulos A, Weber D, Rankin K, Delasalle K, Alexanian R. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 121(5):768-71, 2003. e-Pub 2003. PMID: 12780791.
141. Alexanian R, Weber D, Delasalle K, Cabanillas F, Dimopoulos M. Asymptomatic Waldenstrom's macroglobulinemia. Semin Oncol 30(2):206-10, 2003. e-Pub 2003. PMID: 12720137.
142. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21(1):16-9, 2003. e-Pub 2003. PMID: 12506164.
143. Working Group KOBOIM. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders. A Report of the International Myeloma Working Group. International Myeloma Working Group , British Journal of Hematology 121:749-757, 2003. e-Pub 2003.
144. Weber, D, Dimopoulos M, Delasalle K, Rankin K, Gavino M, Alexanian R. 2-chlorodeoxyadenosine alone or in combination for Waldenstrom’s macroglobulinemia. Seminars in Oncology 30(2):243-247, 2003. e-Pub 2003.
145. Giralt S, Aleman A, Anagnostopoulos A, Weber D, Khouri I, Anderlini P, Molldrem J, Ueno NT, Donato M, Korbling M, Gajewski J, Alexanian R, Champlin R. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant 30(6):367-73, 2002. e-Pub 2002. PMID: 12235521.
146. Alexanian R, Weber D, Giralt S, Delasalle K. Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. Ann Oncol 13(7):1116-9, 2002. e-Pub 2002. PMID: 12176792.
147. Wilder RB, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R. Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone. Cancer 94(5):1532-7, 2002. e-Pub 2002. PMID: 11920511.
148. Mansoor A, Medeiros LJ, Weber DM, Alexanian R, Hayes K, Jones D, Lai R, Glassman A, Bueso-Ramos CE. Cytogenetic findings in lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia. Chromosomal abnormalities are associated with the polymorphous subtype and an aggressive clinical course. Am J Clin Pathol 116:543-9, 2001. e-Pub 2001. PMID: 11601139.
149. Anagnostopoulos A, Dimopoulos MA, Aleman A, Weber D, Alexanian R, Champlin R, Giralt S. High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom's macroglobulinemia. Bone Marrow Transplant 27(10):1027-9, 2001. e-Pub 2001. PMID: 11438816.
150. Alexanian R, Weber D, Giralt S, Dimopoulos M, Delasalle K, Smith T, Champlin R. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 27:1037-43, 2001. e-Pub 2001. PMID: 11438818.
151. Shimoni A, Smith TL, Aleman A, Weber D, Dimopoulos M, Anderlini P, Andersson B, Claxton D, Ueno NT, Khouri I, Donato M, Korbling M, Alexanian R, Champlin R, Giralt S. Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma. Bone Marrow Transplant 27(8):821-8, 2001. e-Pub 2001. PMID: 11477439.
152. Alexanian, R, Weber D, Giralt S, Delasalle K. Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. American Society of Hematology (Blood):163a, 2001. e-Pub 2001.
153. Alexanian R, Weber D, Dimopoulos M, Delasalle K, Smith TL. Randomized trial of alpha-interferon or dexamethasone as maintenance treatment for multiple myeloma. Am J Hematol 65:204-9, 2000. e-Pub 2000. PMID: 11074536.
154. Alexanian, R, Weber D. Thalidomide for resistant and relapsing myeloma. Seminars in Hematology 37:22-25, 2000. e-Pub 2000.
155. Liebross RH, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R. Clinical course of solitary extramedullary plasmacytoma. Radiother Oncol 52:245-9, 1999. e-Pub 1999. PMID: 10580871.
156. Seong C, Delasalle K, Hayes K, Weber D, Dimopoulos M, Swantkowski J, Huh Y, Glassman A, Champlin R, Alexanian R. Prognostic value of cytogenetics in multiple myeloma. Br J Haematol 101:189-94, 1998. e-Pub 1998. PMID: 9576200.
157. Weber DM, Dimopoulos MA, Moulopoulos LA, Delasalle KB, Smith T, Alexanian R. Prognostic features of asymptomatic multiple myeloma. Br J Haematol 97:810-4, 1997. e-Pub 1997. PMID: 9217181.
158. Giralt S, Weber D, Colome M, Dimopoulos M, Mehra R, Van Besien K, Gajewski J, Andersson B, Khouri I, Przepiorka D, von Wolff B, Delasalle K, Korbling M, Seong D, Alexanian R, Champlin R. Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue. J Clin Oncol 15:667-73, 1997. e-Pub 1997. PMID: 9053492.
159. Dimopoulos MA, Weber D, Kantarjian H, Delasalle KB, Alexanian R. HyperCVAD for VAD-resistant multiple myeloma. Am J Hematol 52:77-81, 1996. e-Pub 1996. PMID: 8638645.
160. Daliani D, Weber D, Alexanian R. Light-heavy chain deposition disease progressing to multiple myeloma. Am J Hematol 50:296-8, 1995. e-Pub 1995. PMID: 7485106.
161. Weber D, Dimopoulos M, Sinicrope F, Alexanian R. VAD-cyclosporine therapy for VAD-resistant multiple myeloma. Leuk Lymphoma 19:159-63, 1995. e-Pub 1995. PMID: 8574163.
162. Dimopoulos MA, Weber D, Delasalle KB, Keating M, Alexanian R. Treatment of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors. Ann Oncol 6:49-52, 1995. e-Pub 1995. PMID: 7710983.
163. Moulopoulos LA, Dimopoulos MA, Smith TL, Weber DM, Delasalle KB, Libshitz HI, Alexanian R. Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 13:251-6, 1995. e-Pub 1995. PMID: 7799027.
164. Dimopoulos MA, Kantarjian H, Weber D, O'Brien S, Estey E, Delasalle K, Rose E, Cabanillas F, Keating M, Alexanian R. Primary therapy of Waldenstrom's macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol 12:2694-8, 1994. e-Pub 1994. PMID: 7989946.
165. Weber DM, Dimopoulos MA, Anandu DP, Pugh WC, Steinbach G. Regression of gastric lymphoma of mucosa-associated lymphoid tissue with antibiotic therapy for Helicobacter pylori. Gastroenterology 107:1835-8, 1994. e-Pub 1994. PMID: 7958698.
166. Dimopoulos MA, Weber DM, Kantarjian H, Keating M, Alexanian R. 2Chlorodeoxyadenosine therapy of patients with Waldenstrom macroglobulinemia previously treated with fludarabine. Ann Oncol 5:288-9, 1994. e-Pub 1994. PMID: 7514439.
167. Dimopoulos, MA, Arbuck S, Huber M, Weber D, Luckett R, Delasalle K, R: A. Primary therapy of multiple myeloma with paclitaxel (taxol). . Annals of Oncology 5:757-9, 1994. e-Pub 1994.
168. Dimopoulos MA, Weber D, Delasalle KB, Alexanian R. Combination therapy with interferon-dexamethasone for newly diagnosed patients with multiple myeloma. Cancer 72:2589-92, 1993. e-Pub 1993. PMID: 8402480.
169. Moulopoulos LA, Dimopoulos MA, Weber D, Fuller L, Libshitz HI, Alexanian R. Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. J Clin Oncol 11:1311-5, 1993. e-Pub 1993. PMID: 8315427.
170. Sutton RC, Wever DM, Whimbey EE, Gibbs HR, Dhingra K. Catheter-associated left valvular endocarditis due to corynebacterium. Cancer Bulletin 45:460-465, 1993. e-Pub 1993.

Invited Articles

1. Thomas S, Richards T, Weber D. Novel Agents for Relapsed and/or Refractory Multiple Myeloma. Cancer Journal 15(6):485-93, 2009. e-Pub 2009. PMID: 20010168.
2. Thomas SK, Richards TA, Weber DM. Novel agents for relapsed and/or refractory multiple myeloma. Cancer J 15(6):485-93, 2009. e-Pub 2009. PMID: 20010168.
3. Thomas SK, Richards TA, Weber DM. Lenalidomide in Multiple Myeloma. Best Pract Res Clin Haematol 20((4)):717-735, 2007. e-Pub 2007.
4. Weber DM. Solitary Bone and Extramedullary Plasmacytoma. Hematology (ASH Education Book):373-376, 2005. e-Pub 2005.
5. Weber D. Thalidomide and its derivatives: new promise for multiple myeloma. Cancer Control 10(5):375-83, 2003. e-Pub 2003. PMID: 14581892.
6. Weber D. Thalidomide and its Derivatives: New Promise for Multiple Myeloma. Cancer Control 10(5):375-383, 2003. e-Pub 2003.
7. Dimopoulos M, Weber D, Hester J, Delasalle K, Champlin R, Alexanian R. Intensive sequential therapy for VAD-resistant multiple myeloma. Leukemia & Lymphoma 13:479-484, 1994. e-Pub 1994.
8. Richards TA, Weber DM. Relapsed and/or Refractory Myeloma. Medical Oncology.

Review Articles

1. Dimopoulos MA, Anagnostopoulos A, Weber D. Treatment of plasma cell dyscrasias with thalidomide and its derivatives. J Clin Oncol 21(23):4444-54, 2003. e-Pub 2003. PMID: 14645435.
2. Alexanian R, Weber D, Anagnostopoulos A, Delasalle K, Wang M, Rankin K. Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. Semin Hematol 40(4 Suppl 4):3-7, 2003. e-Pub 2003. PMID: 15015890.
3. Weber D, Treon SP, Emmanouilides C, Branagan AR, Byrd JC, Blade J, Kimby E. Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 30(2):127-31, 2003. e-Pub 2003. PMID: 12720121.
4. Weber DM. Newly diagnosed multiple myeloma. Curr Treat Options Oncol 3(3):235-45, 2002. e-Pub 2002. PMID: 12057069.
5. Alexanian R, Weber D, Liu F. Differential diagnosis of monoclonal gammopathies. Arch Pathol Lab Med 123:108-13, 1999. e-Pub 1999. PMID: 10050782.

Editorials

1. Alexanian R, Weber D. Whither Interferon for myeloma and other hematologic malignancies?. Annals of Internal Medicine (Editorial) 124:264-265, 1996.

Abstracts

1. Patel KK, Shah JJ, Feng L, Lee HC, Manasanch EE, Olsem JB, Morphey AN, Huo XJ, Bashir Q, Thomas SK, Qazilbash MH, Weber DM, Orlowski RZ. Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Post-Transplant Myeloma Patients. Blood 138(Suppl 1):4774, 2021. e-Pub 2021.
2. Thomas SK, Shah JJ, Morin A, Morphey AN, Lee HC, Manasanch EE, Patel KK, Kaufman GP, Iyer SP, Feng L, Amini B, Qazilbash MH, Bashir Q, Saini N, Srour SA, Johnson RJ, Crumpton BN, Stafford MD, Weber DM, Orlowski RZ. Update of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myeloma (MM). Blood 136(Suppl 1):46-47, 2020. e-Pub 2020.
3. Ramdial JL, Ma J, Milton D, Delgado R, Bashir Q, Srour SA, Saini N, Nieto Y, Hosing C, Popat UR, Murphy R, Lee HC, Patel KK, Manasanch EE, Thomas SK, Kaufman GP, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. PBSC Mobilization for Auto-HSCT in Myeloma: Growth Factors Vs Growth Factors + Chemotherapy. Blood 136(Suppl 1):6-7, 2020. e-Pub 2020.
4. Yeung EK, Primeaux BR, Horowitz SB, Shank BR, Lee IY, Kaufamn GP, Lee HC, Manasanch EE, Patel KK, Orlwoski RZ, Weber DM, Thomas SK. Hyperfractionated Cyclophosphamide-Dexamethasone (HyperCy-Dex) with or without Carfilzomib (Car) in Patients (pts) with Multiple Myeloma (MM). Blood 136(Suppl 1):19-20, 2020. e-Pub 2020.
5. Afrough A, Alsfeld LC, Srour SA, Bashir Q, Saini N, Hosing C, Popat UR, Kebriaei P, Shpall EJ, Delgado R, Murphy R, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with t(11;14) Undergoing Autologous Hematopoietic Stem Cell Transplantation. Blood 136(Suppl 1):18-19, 2020. e-Pub 2020.
6. Thomas SK, Cha S, Parshottam SR, Rao SS, Olsem JB, Crumpton BN, Szymura S, Wang Z, Anderson A, Feng L, Lee HC, Manasanch EE, Patel KK, Weber DM, Orlowski RZ, Neelapu SS, Kwak LW. A Novel Therapeutic DNA Vaccine Elicits Reduction of Tumor Clones and Favorable Perturbations in the Immune Microenvironment in Patients (pts) with Untreated Smoldering Waldenström Macroglobulinemia (sWM). Blood 136(Suppl 1):6-7, 2020. e-Pub 2020.
7. Afrough A, Srour SA, Bashir Q, Saini N, Hosing C, Popat UR, Kebriaei P, Shpall EJ, Delgado R, Murphy R, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. Prognostic Impact of Beta 2 Microglobulin in Patients with Immunoglobulin Light-Chain Amyloidosis Undergoing Autologous Hematopoietic Stem Cell Transplantation. Blood 136(Suppl 1):20-21, 2020. e-Pub 2020.
8. Afrough A, Alsfeld LC, Delgado R, Popat UR, Kebriaei P, Oran B, Saini N, Srour SA, Hosing C, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Orlowski RZ, Pinnix CC, Dabaja BS, Thomas SK, Weber DM, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. Blood 136(Suppl 1):22, 2020. e-Pub 2020.
9. Saini N, Ma J, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing C, Nieto Y, Kebriaei P, Alousi AM, Mehta RS, Srour SA, Khouri IF, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. African-Americans Multiple-Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplant Have Similar Survival Outcomes Compared to Whites: A Propensity-Score Matched Analysis. Blood 136(Suppl 1):9-10, 2020. e-Pub 2020.
10. Gaballa MR, Al-Juhaishi T, Bashir Q, Srour SA, Saini N, Ramdial JL, Nieto Y, Murphy R, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. Outcomes of Patients with Multiple Myeloma Who Received VRD Induction, Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance. Blood 136(Suppl 1):14-15, 2020. e-Pub 2020.
11. Ramdial JL, Gaballa MR, Al-Juhaishi T, Bashir Q, Srour SA, Saini N, Nieto Y, Hosing C, Popat UR, Murphy R, Lee HC, Patel KK, Manasanch EE, Thomas SK, Weber DM, Kaufman GP, Orlowski RZ, Champlin RE, Qazilbash MH. Outcomes in Patients with AL (Light-Chain) Cardiac Amyloidosis. Blood 136(Suppl 1):11-13, 2020. e-Pub 2020.
12. Manasanch EE, Han G, Zhang Z, Dang M, Singh M, Khan M, Singh S, Lee HC, Patel KK, Kaufman GP, Amini B, Bashir Q, Srour SA, Nieto Y, Qazilbash MH, Berkova, Z, Lin P, Berry D, Thomas SK, Weber DM, Futreal PA, Wang L, Orlowski RZ, Neelapu SS. Extensive Changes of the Immune Microenvironment Are Associated with Progression from Precursor Stages to Multiple Myeloma. Blood 136(Suppl 1):37-38, 2020. e-Pub 2020.
13. Becnel MR, Horowitz SB, Thomas SK, Iyer SP, Patel KK, Manasanch EE, Weber DM, Kaufman GP, Lee HC, Orlowski RZ. Descriptive Analysis of Isatuximab Use Following Prior Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma. Blood 136(Suppl 1):20-21, 2020. e-Pub 2020.
14. Shank BR, Primeaux B, Horowitz SB, Yeung EK, Lee IY, Kaufman GP, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Weber DM, Thomas SK. Daratumumab (Dara) and hyperfractionated cyclophosphamide (HyperCy)/dexamethasone (Dex) with and without carfilzomib (Car) for the treatment of relapsed/refractory multiple myeloma (RRMM) 38(Suppl 1 (#20528)), 2020. e-Pub 2020.
15. Manasanch EE, Jagannath S, Lee HC, Patel KK, Graham C, Kaufman GP, Thomas SK, Iyer SP, Mailankody S, Korde N, Amini B, Lin P, Berkova Z, Weber DM, Feng L, Lendvai N, Hildebrandt M, Neelapu SS, Orlowski RZ, Landgren O. A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM). Blood 134(Suppl 1 (#3116)), 2019. e-Pub 2019.
16. Kunacheewa C, Feng L, Manasanch EE, Bashir Q, Patel KK, Mehta RS, Kaufman GP, Iyer SP, Thomas SK, Weber DM, Orlowski RZ, Qazilbash MH, Lee HC. Outcomes of Lenalidomide Retreatment with Novel Triplet Regimens in Multiple Myeloma Patients Progressing on Lenalidomide-Based Maintenance Therapy: A Single Center Retrospective Analysis. Blood 134(Suppl 1 (#3198)), 2019. e-Pub 2019.
17. Thomas SK, Cha S, Parshottam SR, Rao SS, Olsem JB, Crumpton BN, Feng L, Lee HC, Manasanch EE, Weber DM, Patel KK, Orlowski RZ, Neelapu SS, Kwak LW. Phase I trial of a novel DNA vaccine in patients (pts) with smoldering Waldenstrom macroglobulinemia (sWM). J Clin Oncol 37(8050), 2019. e-Pub 2019.
18. Kunacheewa C, Patel KK, Lee HC, Thomas SK, Amini B, Srour S, Bashir Q, Qazilbash MH, Weber DM, Neelapu SS, Orlowski RZ, Feng L, Lin P, Manasanch EE. Correlation of minimal residual disease negativity (MRD-) with prognosis in high-risk myeloma (HRM). J Clin Oncol 37(8024), 2019. e-Pub 2019.
19. Saini NY, Patel RO, Varma AN, Bashir QA, Hasan OM, Delgado RU, Rondon GA, Mukherjee AK, Popat UD, Hosing CH, Nieto YA, Kebriaei PA, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Long-Term Durable Responses after Autologous Stem Cell Transplantation in POEMS Syndrome. Blood 132((#4606)), 2018. e-Pub 2018.
20. Cordas Dos Santos DM, Saliba RM, Patel R, Bashir Q, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Popat U, Lee HC, Manasanch EE, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. Older Age As a Prognostic Factor for Overall Survival for Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. Blood 132((#2144)), 2018. e-Pub 2018.
21. DMCD S, Saliba RM, Patel RO, Bashir QA, Hosing CH, Kebriaei PA, Khouri IF, Nieto YA, Popat UD, Lee HC, Manasanch EE, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. Older Age As a Prognostic Factor for Overall Survival for Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. Blood 132((#2144)), 2018. e-Pub 2018.
22. Saini NY, Patel RO, Varma AN, Bashir QA, Delgado RU, Popat UD, Hosing CH, Nieto YA, Kebriaei PA, Alousi AM, Ahmed SA, Mukherjee AK, Mehta RS, Khouri IF, Ciurea SO, Shpall EJ, Omar H, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Melphalan-Based Autologous Transplantation in the Octogenarian Multiple Myeloma Patient Population. Blood 132((#4608)), 2018. e-Pub 2018.
23. Patel RO, Saini NY, Varma AN, Hasan OM, Bashir QA, Delgado RU, Popat UD, Hosing CH, Mukherjee AK, Nieto YA, Kebriaei PA, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Outcome of Autologous Stem Cell Transplantation in Waldenström's Macroglobulinemia. Blood 132((#2149)), 2018. e-Pub 2018.
24. Saini NY, Varma AN, Ma JU, Milton DR, Patel RO, Hasan OM, Bashir QA, Nieto YA, Mukherjee AK, Delgado RU, Rondon GA, Popat UD, Hosing CH, Kebriaei PA, Alousi AM, Ahmed SA, Mehta RS, Ciurea SO, Khouri IF, Shpall EJ, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of t(11;14) on the Outcome of Autologous Transplantation in Multiple Myeloma: A Matched-Pair Analysis. Blood 132((#4607)), 2018. e-Pub 2018.
25. Thomas SK, Shah JJ, Morphey AN, Lee HC, Manasanch EE, Patel KK, Miller CP, Phillips S, Crumpton BN, Johnson RJ, Feng LE, Iyer SW, Behrang A, Weber DM, Orlowski RZ. Updated Results of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myeloma (MM). Blood 132((#1982)), 2018. e-Pub 2018.
26. Varma AN, Saini NY, Sui DA, Milton DR, Hasan OM, Mukherjee AK, Bashir QA, Rondon GA, Srour SA, Popat UD, Hosing CH, Nieto YA, Kebriaei PA, Alousi AM, Mehta RS, Khouri IF, Weber DM, Thomas SK, Manasanch EE, Lee HC, Patel KK, Ciurea SO, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation. Blood 132((#4609)), 2018. e-Pub 2018.
27. Becnel MR, Rubin ML, Nair RA, Manasanch EE, Lee HC, Patel KK, Iyer S, Thomas SK, Weber DM, Orlowski RZ. Effect of Timing of Monoclonal Antibody Therapy on the Time to Next Treatment and Response Rate in Heavily Pre-Treated Patients with Myeloma Who Separately Received Both Daratumumab and Elotuzumab-Based Regimens. Blood 132((#3258)), 2018. e-Pub 2018.
28. Hildebrandt MAT, Callender RA, Belachew AA, Classen CA, Lee HC, Patel KK, Richards TA, Thomas SK, Weber DM, Orlowski RZ, Manasanch EE. Quality of life and cancer worry in a follow-up cohort of patients with asymptomatic monoclonal gammopathies. J Clin Oncol 36((#8049)), 2018. e-Pub 2018.
29. Tabchi SA, Nair RA, Patel KK, Lee HC, Thomas SK, Amini BE, Ahmed SA, Mehta RS, Bashir Q, Qazilbash MH, Weber DM, Orlowski RZ, Alexanian RA, Feng LE, Manasanch EE. The MD Anderson modified cyclophosphamide, bortezomib, doxorubicin, and dexamethasone (mCBAD) for the treatment of newly diagnosed (NDMM) and relapsed/refractory multiple myeloma (RRMM). J Clin Oncol 36((#8044)), 2018. e-Pub 2018.
30. Aboudalle IM, Khan MA, Feng LE, Thomas SK, Manasanch EE, Patel KK, Medeiros JE, Mehta RO, Bashir Q, Qazilbash MH, Orlowski RZ, Weber DM, Hu SH, Lee HC. Characteristics and outcomes of primary plasma cell leukemia in the era of novel agents: Single center experience. J Clin Oncol 36((#8054)), 2018. e-Pub 2018.
31. Manasanch EE, Claussen CM, Dong WE, Lee HC, Thomas SK, Patel KK, Reed VK, Dabaja BS, Milgrom S, Pinnix CC, Parmar SI, Bashir QA, Qazilbash MH, Amini BE, Rayomond AL, Orlowski RZ, Feng LE, Weber DM. A Clinical Model of Progression to Multiple Myeloma in Solitary Plasmacytoma. Blood 130(Suppl 1 (5367)), 2017. e-Pub 2017.
32. Thomas SK, Shah JJ, Lee HC, Manasanch EE, Weber DM, Patel KK, Feng LE, Amini BE, Morphey A, Crumpton BR, Phillips SA, Miller CA, Gonzalez MA, Orlowski RZ. Preliminary Results of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant in Patients with Multiple Myeloma. Blood 130(Suppl 1 (#840)), 2017. e-Pub 2017.
33. Chaudhry M, Steiner RA, Claussen CM, Patel KK, Lee HC, Weber DM, Thomas SK, Feng CH, Kramer M, Amini BE, Orlowski RZ, Feng LE, Manasanch EE. Carfilzomib-Based Combination Regimens Are Highly Effective Frontline Therapies for Multiple Myeloma and Waldenström's Macroglobulinemia. Blood 130(Suppl 1 (#1880)), 2017. e-Pub 2017.
34. Patel KK, Shah JJ, Feng LE, Lee HC, Manasanch EE, Thomas SK, Weber DM, Munoz SC, Morphey AS, Bashir Q, Qazilbash MH, Orlowski RZ. Update on a Phase II Study of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. Blood 130(Suppl 1 (#0437)), 2017. e-Pub 2017.
35. Claussen CM, Chuang TA, Chaudhry MA, Lee HC, Patel KK, Bashir QA, Parmar SI, Ahmed SA, Mehta RS, Thomas SK, Richards TA, Nieto YA, Shpall EJ, Qazilbash MH, Amini BE, Davis RE, Neelapu SS, Weber DM, Orlowski RZ, Feng LE, Manasanch EE. Gene Expression Profiling Is a Strong Predictor of Clinical Outcomes in Newly Diagnosed Multiple Myeloma. Blood 130(Suppl 1 (#4365)), 2017. e-Pub 2017.
36. Manasanch EE, Lee HC, Patel KK, Weber DM, Lee HJ, Thomas SK, Chen W, On O, Badillo M, Graham V, Lei FE, McCarthy MS, Orlowski RZ, Wang M. A Phase I/II Study of Pomalidomide and Dexamethasone with Growth Factor Support in Patients with Relapsed/Refractory Multiple Myeloma. Blood 130(Suppl 1 (#3090)), 2017. e-Pub 2017.
37. Mathur RO, Zhang ZH, He JI, Galetto RO, Gouble AG, Sotinel IC, Filipe ST, Gariboldi AN, Veeramachaneni TA, Manasanch EE, Thomas SK, Lee HC, Patel KK, Weber DM, Davis RE, Orlowski RJ, Smith JU, Yang JI, Neelapu SS. Universal SLAMF7-Specific CAR T-Cells As Treatment for Multiple Myeloma. Blood 130(Suppl 1 (#502)), 2017. e-Pub 2017.
38. Mathur RO, Barnett BE, Hermanson DA, He J, Zhang ZH, Rengarajan SR, Codde RE, Wang XI, Tan YE, Martin CH, Smith JE, Lee HC, Manasanch EE, Thomas SK, Patel KK, Weber DM, Davis E, Orlowski RZ, Ostertag EM, Shedlock DE, Ji Y, Neelapu SS. B-Cell Maturation Antigen (BCMA)-Specific, CentyrinTM-Based, PiggyBacTM-Transposed CAR-T Memory Stem Cells Are Effective Against p53-/- and Patient-Derived Multiple Myeloma Tumors. Blood 130(Suppl 1 (#3068)), 2017. e-Pub 2017.
39. Qazilbash MH, Stadtmauer EA, Baladandayuthapani VE, Lin HE, Tross BE, Honhar ME, Cha SC, Kim KU, Popescu MI, Shah NI, Bashir QA, Patel KK, Lee VY, Shpall EJ, Weber DM, Thomas SK, Orlowski RZ, Kerr NA, Garfall AL, Cohen AD, Vogl DT, Dengel KA, June CH, Champlin RE, Kwak LW. Randomized Phase II Trial of Combination Idiotype Vaccine and Adoptive Cell Transfer of Costimulated Autologous T Cells in Patients with Multiple Myeloma Post-Autotransplantation. Blood 130(Suppl 1 (#3193)), 2017. e-Pub 2017.
40. Qazilbash, MH, Stadtmauer, EA, Baladandayuthapani, V, Lin, H, Tross, BM, Honhar, M, Cha, S, Kim, K, Rao, SS, Popescu, M, Shah, N, Bashir, Q, Patel, K, Shpall, EJ, Weber, DM, Thomas, SK, Shah, JJ, Orlowski, RZ, Kerr, ND, Garfall, AL, Cohen, AD, Dengel, K, June, CH, Champlin, RE, Kwak, L. Randomized Phase II Trial of Combination Idiotype Vaccine and Anti-CD3/Anti-CD28 Costimulated Autologous T Cells in Patients with Multiple Myeloma Post-Autotransplantation. Blood (58th ASH Annual Meeting Abstracts) 128(22):4548, 2016. e-Pub 2016.
41. Mohyuddin, GR, Faisal, MS, Shah, N, Bashir, Q, Hosing, C, Patel, K, Popat, UR, Parmar, S, Rondon, G, Delgado, R, Weber, DM, Shah, JJ, Thomas, S, Manasanch, EE, Orlowski, RZ, Champlin, RE, Qazilbash, MH. A Case Control Study of Syngeneic Transplantation Versus Autologous Transplantation for Multiple Myeloma: Two Decades of Experience at MD Anderson. Blood (58th ASH Annual Meeting Abstracts) 128(22):4613, 2016. e-Pub 2016.
42. Claussen, CM, Lee, HC, Shah, JJ, Richards, T, Shah, N, Patel, K, Bashir, Q, Parmar, S, Thomas, S, Nieto, Y, Qazilbash, MH, Davis, RE, Neelapu, SS, Weber, DM, Orlowski, RZ, Feng, L, Manasanch, EE. Gene Expression Profiling Predicts Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting. Blood (58th ASH Annual Meeting Abstracts) 128(22):5628, 2016. e-Pub 2016.
43. Manasanch, E, Claussen, CM, Dong, W, Shah, J, Lee, H, Thomas, S, Reed, VK, Dabaja, BS, Milgrom, S, Pinnix, CC, Parmar, S, Shah, N, Patel, K, Bashir, Q, Qazilbash, M, Orlowski, R, Weber, D. Clinical characteristics, outcomes and predictors of progression to multiple myeloma (MM) in 61 patients with solitary plasmacytoma. Clin Lymph, Myel, Leuk 15(Supplement 3):e181-e182, 2015. e-Pub 2015.
44. Richards, TA, Shah, J, Horowitz, S, Shah, R, Comer, J, Yu, J, Feng, Sevin, A, Dabaja, B, Pinnix, C, Milgrom, S, Reed, V, Manasanch, E, Thomas, S, Shah, N, Qazilbash, MH, Atmar, J, Mullen, E, Lee, H, Wang, M, Alexanian, R, Orlowski, R, Weber, DM. Characteristics of Myeloma (MM) Patients (pts) with Central Nervous System (CNS) Involvement. Clin Lymph, Myel, Leuk 15(Supplement 3):e117 - e118, 2015. e-Pub 2015.
45. Richardson PG, Schlossman RL, Alsina M, Weber DM, Coutre SE, Gasperretto C, Mukhopadhyay S, Ondovik MS, Khan M, Paley CS, Lonial S. Time To Event Analyses in PANORAMA 2: A Phase 2 Study Of Panobinostat, Bortezomib, and Dexamethasone In Patients With Relapsed and Bortezomib-Refractory Multiple Myeloma. Blood 122(2013), 2013. e-Pub 2013.
46. Thomas, S, Haygood, TM, Qazilbash, MH, Melendez, AG, Galvis, R, Delasalle, KB, Feng, L, Richards, TA, Samaniego, F, Wang, L, Shah, JJ, Orlowski, RZ, Weber, DM. A Phase II Trial Of Bortezomib-Rituximab Followed By Autologous Stem Cell Harvest (SCH) and Cladribine-Cyclophosphamide-Rituximab (2CdA-Cy-Rit) Consolidation As Primary Therapy Of Waldenström's Macroglobulinemia (WM). Blood 122:4396, 2013. e-Pub 2013.
47. Feng, L, Oki, Y, Qazilbash, M, Muzzafar, T, Weber, DM, Fowler, N, Popat, UR, Thomas, SK, Fanale, MA, Nieto, Y, Shah, N, Bashir, Q, Hagemeister, FB, Orlowski, RZ, Shah JJ. Plasmablastic Lymphoma: 28 Patient Single Institution Experience. Blood 122:4310, 2013. e-Pub 2013.
48. Shah, JJ, Zonder, J, Bensinger, WI, Cohen, AD, Kaufman, JL, Nooka, AK, Weber, DM, Hilder, B, Rush, SA, Ptaszynski, A, Walker, D, Orlowski RZ. Prolonged Survival and Improved Response Rates With ARRY-520 In Relapsed/Refractory Multiple Myeloma (RRMM) Patients With Low α-1 Acid Glycoprotein (AAG) Levels: Results From a Phase 2 Study. Blood 122:285, 2013. e-Pub 2013.
49. Mohite, S, Baladandayuthapani, V, Thomas, SK, Weber, DM, Wang, M, Alexanian, R, Qazilbash, MH, Popat, UR, Champlin, RE, Shah, N, Bashir, Q, Parmar, S, Nieto, Y, Ahmed, S, Orlowski, RZ, Shah, JJ. Circulating Plasma Cells By Routine Complete Blood Count Identify Patients With Similar Outcome As Plasma Cell Leukemia. Blood 122:5356, 2013. e-Pub 2013.
50. Zaman, S, Thomas, SK, Alexanian, R, Shah, JJ, Weber, DM, Wang, M, Holloway, AN, Baladandayuthapani, V, Lin, HY, Fu, M, Stellrecht, CM, Partovi MD, C, Gandhi, V. Phase II Study Of The c-MET Inhibitor ARQ 197 (Tivantinib) In Patients With Relapsed Or Relapsed/Refractory Multiple Myeloma (RRMM). Blood 122:1953, 2013. e-Pub 2013.
51. Shah, RA, Thomas, SK, Weber, DM, Wang, M, Alexanian, R, Orlowski, RZ, Shah JJ. Feasibility and Activity Of Bortezomib-Based Therapy In Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Carfilzomib. Blood 122:1994, 2013. e-Pub 2013.
52. Shah, J, Baladandayuthapani, V, Weber, DM, Thomas, SK, Alexanian, R, Wang, W, Qazilbash, MH, Champlin, RE, Shah, N, Bashir, Q, Popat, UR, Nieto, Y, Ahmed, S, Parmar, S, Orlowski RZ. Phase II Study Of The Combination Of MLN 9708 With Lenalidomide As Maintenance Therapy Post Autologous Stem Cell Transplant In Patients With Multiple Myeloma. Blood 122:1983, 2013. e-Pub 2013.
53. Shah, J, Feng, L, Thomas, SK, Weber, DM, Wang, M, Hilder, B, Alexanian, R, Orlowski, RZ. Phase 1 Study Of The Novel Kinesin Spindle Protein Inhibitor ARRY-520 + Carfilzomib (Car) In Patients With Relapsed And/Or Refractory Multiple Myeloma (RRMM). Blood 122:1982, 2013. e-Pub 2013.
54. Alsina, M, Richardson, PG, Schlossman, RL, Weber, DM, Coutre, DE, Gasparetto, C, Mukhopadhyay, S, Ondovik, MS, Khan, MH, Paley, CS, Lonial, S. Clinical response by baseline characteristics in patients (pts) with relapsed and bortezomib (BTZ)-refractory multiple myeloma treated with panobinostat (PAN), BTZ, and dexamethasone (DEX; PANORAMA 2). J Clin Oncol (abstract) 31((suppl)), 2013. e-Pub 2013.
55. Khan, D, Patel, K, Thomas, SK, Weber, DM, Delasalle, KB, Hosing, CM, Popat, UR, Bashir, Q, Shah, Shah, N, Parmar, S, Champlin, RE, Qazilbash, M. Feasibility of Hematopoietic Stem Cell Collection and Cryopreservation in Waldenstrom's Macroglobulinemia. Blood (ASH Annual Meeting Abstracts) 120:4128, 2012. e-Pub 2012.
56. Shah, JJ, Orlowski, RZ, Thomas, SK, Alexanian, R, Wang, M, Qazilbash, MH, Popat, UR, Parmar, S, Shah, N, Bashir, Q, Champlin, RE, Weber, DM. Final Results of a Phase I/II Trial of the Combination of Concurrent Lenalidomide, Thalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Myeloma. Blood (ASH Annual Meeting Abstracts) 120:75, 2012. e-Pub 2012.
57. Shah, JJ, Hegde, A, Zhou, X, Thomas, S, Wang, M, Weber, DM, Alexanian, R, Orlowski, RZ, Vadhan-Raj, S. Effects of Multiple Myeloma (MM) Therapy and Type of Thromboprophylaxis On the Incidence and Timing of Venous Thromboembolism (VTE) and Factors Predictive of VTE. Blood (ASH Annual Meeting Abstracts) 120:2244, 2012. e-Pub 2012.
58. Thomas, SK, Delasalle, KB, Shah, JJ, Wang, L, Orlowski, RZ, Weber, DM. Impact of Rituximab On the Treatment of Waldenström's Macroglobulinemia (WM). Blood (ASH Annual Meeting Abstracts 120:2734, 2012. e-Pub 2012.
59. Shah, JJ, Thomas, SK, Weber, DM, Wang, M, Aexanian, R, Qazilbash, MH, Bashir, Q, Parmar, S, Shah, N, Popat, UR, Orlowski, RZ. Phase 1/1b Study of the Efficacy and Safety of the Combination of Panobinostat + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 120:4081, 2012. e-Pub 2012.
60. Kuiatse, I, Thomas, SK, Weber, DM, Stein, AM, Wang, M, Shah, JJ, Treon, SP, Ansell, SM, Orlowski, RZ. Inhibition of Spleen Tyrosine Kinase with Fostamatinib Shows Pre-Clinical Activity Against Models of Waldenström Macroglobulinemia. Blood (ASH Annual Meeting Abstracts) 120:3723, 2012. e-Pub 2012.
61. Shah, JJ, Weber, DM, Thomas, DK, Alexanian, R, Wang, M, Qazilbash, MH, Parmar, S, Shah, N, Bashir, Q, Popat, UR, Hilder, B, Orlowski RZ. Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor ARRY-520 + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 120:4082, 2012. e-Pub 2012.
62. Dorkhom, SJ, Zaman, S, Thomas, SK, Alexanian, R, Shah, JJ, Weber, DM, Wang, M, Anderson, ML, Baladandayuthapani, V, Lin, YH, Fu, M, Stellrecht, CM, Partovi MD, C, Gandhi, VV, Orlowski RZ. Phase II Study of the c-Met Inhibitor ARQ 197 (Tivantinib) in Patients with Relapsed Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 120:2976, 2012. e-Pub 2012.
63. Dimopoulos MA, Hussein M, Swern AS, and Donna M Weber DM. Long-Term Outcomes and Safety of Continuous Lenalidomide Plus Dexamethasone (Len+Dex) Treatment in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM). Blood (ASH 118, 2011. e-Pub 2011.
64. Liu Z, Zheng Y, Li H, Lu Y, Weber DM, He J, Kwak LW, Yi Q. Autocrine Sonic Hedgehog Protects Multiple Myeloma Cells From Apoptosis and Enhances Drug Resistance. Blood 118, 2011. e-Pub 2011.
65. Richardson RG, Alsina M, Weber DM, Coutre SE, Lonial S, Gasparetto C, Warsi G, Ondovik M, Mukhopadhyay S, Snodgrass S, Schlossman R. Phase II Study of the Pan-Deacetylase Inhibitor Panobinostat in Combination with Bortezomib and Dexamethasone in Relapsed and Bortezomib-Refractory Multiple Myeloma (PANORAMA 2). Blood 118, 2011. e-Pub 2011.
66. Dimopoulos MA, Orlowski RZ, Niesvizky R, Lonial S, Brandenburg NA, Weber DM. Lenalidomide and dexamethasone (LEN plus DEX) treatment in relapsed/refractory multiple myeloma (RRMM) patients (pts) and risk of second primary malignancies (SPM): Analysis of MM-009/010. Journal of Clinical Oncology 29(15 (suppl)), 2011. e-Pub 2011.
67. Harousseau JL, Dimopoulos MA, Wang M, Corso A, Chen C, Attal M, Spencer A, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica 95(10):1738-44, 2010. e-Pub 2010.
68. Richardson P, Weber D, Mitsiades C, Dimopoulos M, Harousseau J, Howe J, Graef T, Byrne C, Anderson K, Siegel D. Phase I study of combined vorinostat (V), lenalidomide (L), and dexamethasone (D) in patients (pts) with relapsed or refractory multiple myeloma (MM). Journal of Clinical Oncology 28(15 (suppl)), 2010. e-Pub 2010.
69. Alsina M, Lonial S, Weber D, Coutre S, Kang B, Glynos T, Warsi G, Snodgrass S, Richardson P. PANORAMA 2: A phase II study of panobinostat (LBH589) in combination with bortezomib (BTZ) and dexamethasone (DEX) in patients with relapsed and BTZ-refractory multiple myeloma (MM). Journal of Clinical Oncology 28(15 (suppl)), 2010. e-Pub 2010.
70. Reed VK, Shah JJ, Mazloom A, Weber DM, Phan J, Orlowski RZ, Thomas SK, Wang M, Alexanian R, Dabaja BS. Outcome and prognostic factors in solitary plasmacytoma. Journal of Clinical Oncology 28(15 (suppl)), 2010. e-Pub 2010.
71. Siegel D, Weber DM, Mitsiades CS, Dimopoulos MA, Harousseau JL, Rizvi S, Howe J, Reiser D, Byrne C, Anderson KC, Richardson P. Combined Vorinostat, Lenalidomide and Dexamethasone Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase I Study. Blood (ASH Annual Meeting) 114:305, 2009. e-Pub 2009.
72. Thomas SK, Feng L, Delasalle KB, Wang M, Shah J, Orlowski RZ, Alexanian R, Weber DM. Prognostic Factors for Survival After 2-CdA-Based Therapy for Symptomatic Waldenström Macroglobulinemia (WM) Stratify Patients Into Low- and High-Risk Groups. Blood (ASH Annual Meeting) 114:1668, 2009. e-Pub 2009.
73. Shah N, Weber DM, Wang M, Thomas SK, Shah JJ, Giralt S, Alexanian R, Orlowski RZ, Qazilbash M, Avery T. Survival Disparities Between African-American and Caucasian Patients with Multiple Myeloma Are Blunted in the Era of Novel Therapeutics and Autologous Stem Cell Transplantation. Blood (ASH Annual Meeting) 114:1395, 2009. e-Pub 2009.
74. Shah N, Ahmed KF, Qureshi S, Shah J, Orlowski RZ, Weber DM, Hosing C, Popat U, Alousi A, Champlin RE, Giralt S, Qazilbash M. Durable Remission with Salvage Autotransplants in Patients with Multiple Myeloma. Blood (ASH Annual Meeting) 114:1227, 2009. e-Pub 2009.
75. Jagannath S, Weber DM, Sobecks R, Schiller GJ, Lupinacci L, Reiser D, Allen J, Rizvi S. The Combination of Vorinostat and Bortezomib Provides Long-Term Responses in Patients with Relapsed or Refractory Multiple Myeloma. Blood (ASH Annual Meeting) 114:3886, 2009. e-Pub 2009.
76. Delasalle K, Wang M, Weber DM, Giralt SA, Thomas SK, Shah JJ, Handy B, Orlowski RZ, Alexanian R. Curability of Multiple Myeloma. Blood (ASH Annual Meeting) 114:3864, 2009. e-Pub 2009.
77. Lonial S, Baz R, Swern AS, Dm W, Dimopoulos MA. Neutropenia Is a Predictable and Early Event in Affected Patients with Relapsed /Refractory Multiple Myeloma Treated with Lenalidomide in Combination with Dexmethasone. Blood (ASH Annual Meeting) 114:2879, 2009. e-Pub 2009.
78. Shah N, Weber D, Orlowski R, Wang M, Thomas S, Richards T, Giralt S, Qazilbash M, Alexanian R, Shah J. Role of Autologous Stem Cell Transplant after Induction Therapy with Bortezomib-Lenalidomide or Bortezomib-Thalidomide in Newly Diagnosed Multiple Myeloma Patients 27(15s), 2009. e-Pub 2009.
79. Weber D, Jagannath S, Sobecks R, Schiller G, Chiacchierini L, Reiser D, Oerth C, Garcia-Vargas J, Rizvi S. Combination of Vorinostat Plus Bortezomib for the Treatment of Patients with Multiple Myeloma Who Have Previously Recieved Bortezomib. Blood 112, 2008. e-Pub 2008.
80. Qazilbash M, Silba R, Pelosini M, Hosing C, Mendoza F, Han E, Wang M, Weber D, Alousi A, Anderlini P, Kebriaei P, Khouri I, Popat U, De Lima M, Orlowski R, Champlin R, Giralt S. A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma. Blood 112, 2008. e-Pub 2008.
81. Ishak J, Dimopoulos M, Weber D, Knight R, Shearer A, Caro J. Declining Rates of Adverse Events and Dose Modifications with Lenalidomide in Combination with Dexamethasone. Blood 112, 2008. e-Pub 2008.
82. Siegel D, Weber D, Mitsiades C, Rizvi S, Garcia-Vargas J, Howe J, Reiser D, Anderson K, Richardson P. A Phase I Study of Vorinostat in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma. Blood, 2008. e-Pub 2008.
83. Cole S, Saliba R, Pelosini M, Mendoza F, Weber D, Wang M, Thomas S, Orlowski R, Shah J, Alousi A, Hosing C, Popat U, Kebriaei P, Anderlini P, Khouri I, Champlin R, Giralt S, Qazilbash M. Reduced-Intensity Regimens for Allogeneic Stem Cell Transplantation Improve the OUtcome in Advanced Multiple Myeloma. Blood 112, 2008. e-Pub 2008.
84. Weber D, Badros A, Jagannath S, Siegel D, Richon V, Rizvi S, Garcia-Vargas J, Reiser D, Anderson K. Vorinostat Plus Bortezomib for the Treatment of Relapsed/Refractory Multiple Myeloma: Early Clnical Experience. Blood 112, 2008. e-Pub 2008.
85. San Miguel J, Dimopoulos M, Stadtmauer E, Rajkumar V, Siegel D, Bravo M, Olesnyckyj M, Knight R, Zeldis J, Harousseau J, Weber D. Longer Duration of Treatment and Maintenance of Best Response with Lenalidomide and Dexamethasone Prolongs Overall Survival in Patients with Relapsed or Refractory Multiple Myeloma. Blood 112, 2008. e-Pub 2008.
86. Chanan-Khan A, Dimopoulos M, Weber D, Apencer A, Attal M, Belch A, Corso A, Fu T, Zeldis J, Olesnyckyj M, Knight R, Lonial S. Safety and Efficacy Outcomes with Lenalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma were Not Significantly Different for the Treatment of Patients with or without High-Risk Disease or Elderly Status. Blood 112, 2008. e-Pub 2008.
87. Kazmi S, Mendoza F, Weber D, Wang M, Hosing C, Khouri I, Anderlini P, De Lima M, Kebriaei P, Popat U, Champlin R, Giralt S, Qazilbash M. High-Dose Topotecan, Melphalan and Cyclophosphamide (TMC) with Autologous Stem Cell Support for Multiple Myeloma. Blood 112, 2008. e-Pub 2008.
88. Rakkhit R, Delasalle K, Gavino M, Thomas S, Dimopoulos M, Hagemeister F, Rodriguez, A, McLaughlin P, Alexanian R, Weber D. Incidence of Transformation to Large Cell Lymphoma and to Second Malignancies in Symptomatic Patients with Waldenstrom's Macroglobulinemia (WM) Treated with Cladribine (2CdA) Combination Induction Therapy. Blood 112, 2008. e-Pub 2008.
89. Thomas S, Hosing C, Delasalle K, Gavino M, Popat U, Qazilbash M, Giralt S, Weber D. Success Rates of Autologous Stem Cell Collection in Patients with. 5th International Workshop on Waldenström’s, 2008. e-Pub 2008.
90. Weber DM, Jagganath S, Mazumder A, Sobecks R, Schiller GJ, Gavino M, Meehan K, McFadden C, Chen C, Ricker JL, Rizvi S, Oerth C, Brownell P, Sanz-Rodriguez C, Hussein MA. Phase I trial of oral vorinostat in combination with bortezomib in advanced multiple myeloma. Haematologica 93((s1)), 2008. e-Pub 2008.
91. Weber DM, Spencer A, Wang M, Cheri C, Attal M, Niesvizky R, Prince M, Yu Z, Knight R, Dimopoulos MA. The efficacy and safety of lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma patients with impaired renal function. Journal of Clinical Oncology 26(15S):464s, 2008. e-Pub 2008.
92. Giralt S, Thandi R, Qazilbash M, Mendoza F, Han E, Hosing C, Wang M, Thomas S, Alexanian R, Champlin R, Weber D. Retrospective Comparison of Transplant Outcomes in Patients with Multiple Myeloma According to Induction Therapy with Thalidomide/Dexamethasone (TD) with or without Bortezomib (VTD). Blood 110(948), 2007. e-Pub 2007.
93. San Miguel JF, Dimopoulos M, Weber D, Olesnyckyj M, Yu Z, Zeldis J, Knight R, and Rajkumar V. Dexamethasone dose adjustments relapsed/refractory multiple myeloma who are treated with lenalidomide/dexamethasone (MM009/010 Sub-Analysis). Blood 110:1172, 2007. e-Pub 2007.
94. Qazilbash M, Saliba R, Parikh G, Hosing C, Mendoza F, Qureshi S, Weber DM, Wang M, Flosser T, Couriel D, Kebriaei P, Popat U, Alousi A, de Lima M, Champlin R, Giralt S. Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan Is Safe and Effective for Autotransplantation for Multiple Myeloma. Blood 110(942), 2007. e-Pub 2007.
95. San Miguel J, Dimopoulos M, Weber D, Olesnyckyj M, Yu Z, Zeldis J, Knight R, Rajkumar V. Dexamethasone Dose Adjustments Seem to Result in Better Efficacy and Improved Tolerability in Patients with Relapsed/Refractory Multiple Myeloma who are Treated with Lenalidomide/Dexamethasone (MM009/010 Sub-Analysis). Blood, 2007. e-Pub 2007.
96. Weber D, Knight R, Chen C, Spencer A, Yu Z, Zeldis J, Olesnyckvj M, and Dimopoulos M. Prolonged overall survival with lenalidomide plus dexamethasone alone in patients with relapsed or refractory multiple myeloma. Blood 110:412, 2007. e-Pub 2007.
97. Parikh G, Saliba R, Lahoti A, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Popat U, Alousi A, Champlin RE, Giralt S, and Qazilbash MH. Autotransplantation in patients with multiple myleoma and concurrent renal failure is safe and feasible and associated with recovery of renal function in > 30% of patients. Blood 110:5126, 2007. e-Pub 2007.
98. Foa R, Weber D, Dimopoulos M, Olesnyckyj M, Yu A, Zeldis J, Knight R, Chanan-Khan A. Lenalidomide/Dexamethasone Improves Response and Prolonges Time to Progression, Even in Patients with IgA Multiple Myeloma. Sub-Analysis of the MM-009/010 Studies. Blood 110, 2007. e-Pub 2007.
99. Qazilbash MH, Saliba R, Parikh GC, Hosing C, Mendoza F, Weber DM, Wang M, Thomas SK, Flosser TS, Kebriaei P, Popat U, Alousi A, de Lima M, Champlin R, and Giralt S. A non-myeloablative regimen of fludarabine and melphalan is safe and well tolerated for allogeneic transplantation in multiple myeloma. Blood 110:3032, 2007. e-Pub 2007.
100. Harousseau JL, Weber D, Dimopoulos M, Olesnyckyj M, Yu Z, Zeldis J, Knight R, and Siegel D. Relapsed/Refractory multiple myeloma patients treated with lenalidomide/dexamethasone who achieve a complete or near complete response have longer overall survival and time to progression compared with patients achieving a partial reponse. Blood 110:3598, 2007. e-Pub 2007.
101. Wright J, Weber D, Thomas SK, Wang M, Alexanian R, Hawkins VE, and Vadhan-Raj S. Characteristics of patients experiencing thromboembolic events during treatmetn for mutiple myeloma: aspirin may not be adequate thrombophylaxis in patients with multiple risk factors. Blood 110:1882, 2007. e-Pub 2007.
102. Vadhan-Raj S, Wever DM, Wang M, Giralt S, Thomas SK, Alexanian R, Zhou X, Patel P, Bueso-Ramos CE, Newman R, Aggarwal BB. Curcumin downregulates NF-kB and related genes in patients with multiple myeloma: results of a Phase I/II study. Blood 110:1177, 2007. e-Pub 2007.
103. Weber DM, Jagannath S, Mazumder A, Sobecks R, Schiller GJ, Gavino M, Sumbler C, McFadden C, Chen C, Ricker JL, Rizvi S, Oerth C, Brownell P, and Hussein MA. Phase I trial of oral vorinostat (suberolynalide hydoxamic acid, SAHA) in combination with bortezomib in patients wiht advanced multiple myeloma. Blood 110(1172), 2007. e-Pub 2007.
104. Silva L, Weber D, Wang M, Han E, Mendoza F, de Lima M, Qazilbash M, Champlin R, Giralt S. Myeloma with AL amyloidosis: 10 years experience with stem cell transplant. Blood 110:5112, 2007. e-Pub 2007.
105. Chanan-Khan AA, Dimopoulos M, Weber D, Olesnysckyj M, Yu Z, Zeldis J, Knight R, and San Miguel J. ECOG Performance status affects efficacy, but not safety, of lenalidomide/dexamethasone in relapsed/refractory multiple myeloma (MM009/010 Sub-Analysis). Blood 110:2721, 2007. e-Pub 2007.
106. Thomas S, Delasalle K, Gavino M, Wang M, Alexanian R, dm W. 2-CDA-cycophosphamide + rituximab for symptomatic Waldenstrom’s macroglobulinemia. Haematologica. Haematologica 92 (s2):228, 2007. e-Pub 2007.
107. Richards T, Horowitz S, Temple S Nguyen C, Thomas S Wang M, Giralt S, Weber DM. Evaluation of multiple myeloma response by free light chain assay. Haematologica 92(6):205, 2007. e-Pub 2007.
108. Delasalle K, Wang M, Thomas S, Weber D, Alexanian R. High response rate with BCD combination for relapsing multiple myeloma. Haematologica 92((s2):189), 2007. e-Pub 2007.
109. Wang M, Delasalle K, Thomas S, s, Qazilbash M, Giralt S, Weber DM, Alexanian R. Early transplant is useful for older patients with multiple myeloma. Haematologica 92 (s2):189, 2007. e-Pub 2007.
110. Lonial S, Knight R, Dimopoulos M, Chanan-Khan A, San Miguel J, Facon T, Yu Z, Zeldis J, Olesnyckyi M, Weber D. Effect of len/dex in mm in different age groups. Haematoogica((s2)):172, 2007. e-Pub 2007.
111. Wang M, Knight R, Dimopoulos M, Siegel D, Rajkumar SR, Facon T, Alexanian R, Yu Z, Zeldis J, Lesnyckij M, Weber DM. Effect of len/dex in mm despite thal resistance. Haematologica 92((s2)):172, 2007. e-Pub 2007.
112. Thomas S, Delasalle K, Wang M, Alexanian R, Weber DM. Rituximab alone or in combination in the frontline treatment of Waldenstrom's macroglobulinemia. Haematologica 92 (s2):87-88, 2007. e-Pub 2007.
113. Weber DM. Lenalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma. Haematologica 92 (s2):22-23, 2007. e-Pub 2007.
114. Weber DM. High response rate with BCD combination for relapsing multiple myeloma. Haematologica 91 (s2):158, 2007. e-Pub 2007.
115. Alexanian R, Weber D. Solitary bone and extramedullary plasmacytoma. Haematologica 92(s2):57-58, 2007. e-Pub 2007.
116. Wang M, Knight R, Dimopoulos M, Siegel D, Rajkumar SV, Facon T, Alexanian R, Yu Z, Zeldis J, Olesnyckyj M, Weber D. Lenalidomide in Combination with Dexamethasone Was More Effective Than Dexamethasone in Patients Who Have Received Prior Thalidomide for Relapsed or Refractory Multiple Myeloma. Blood:1014a, 2006. e-Pub 2006.
117. Chanana-Khan, Yu Z, Weber D, Chen C, Niesvizky R, Spencer A, Attal M, Belch A, Prince M, Olesnyckyi M, Knight R, Zeldis J, Dimopoulos M. Lenalidomide (L) in Combination with Dexamethasone (D) Significantly Improves Time to Progression (TTP) in Non-Stem Cell Transplant Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM): Analysis from MM-009 and MM-010 Randomized Phase III Clinical Trials. Blood:1015a, 2006. e-Pub 2006.
118. Qazilbash M, Saliba R, Hosing C, Mendoza F, Qureshi S, Weber D, Weber D, Wang M, Flosser T, Couriel D, De Lima M, Kebriaei P, Popat U, Alousi A, Champlin R, Giralt S. Autologous Stem Cell Transplantation for Elderly Patients with Multiple Myeloma. Blood:page 450b, 2006. e-Pub 2006.
119. Stadmauer E, Weber D, Dimopoulos M, Belch A, Attal M, Prince M, Olesnyckyj M, Yu Z, Zeldis J, Knight R. Lenalidomide in Combination with Dexamethasone Is More Effective Than Dexamethasone at First Relapse in Relapsed Multiple Myeloma. Blood:page 1012a, 2006. e-Pub 2006.
120. Ahmed B, Saliba R, Ashraf N, Mendoza F, Hosing C, Flosser T, Weber D, Wang M, Couriel D, Popat U, Kebriaei P, Alousi A, Champlin R, Giralt S, Qazilbash M. Deletion of the Short Arm of Chromosome 1 (del 1 p) Is the Strongest Predictor of Poor Outcome in Myeloma Patients Undergoing an Autotransplant. Blood:Page 881a, 2006. e-Pub 2006.
121. Weber D, Wang M, Chen C, Belch A, Stadmauer E, Niesvisky R, Yu, Olesnyckyi M, Zeldis J, Knight R, Dimopoulos M. Lenalidomide plus high dose dexmethasone provides improved overall survival compared to high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): Results of 2 phase III studies (MM-009, MM-010) and subgroup analysis of patients with impaired renal function. Blood 18S:24, 2006. e-Pub 2006.
122. Wang M, Knight R, Dimopoulos M, SiegelD, Rajkumar SV, Facon T, Yu Z, j Z, Olesnycky J, Weber DM. Lenalidomide in combination with dexamethasone is more effective than dexamethasone in patients who have received prior thalidomide in relapsed or refractory multiple myeloma (MM). Journal of Clinical Oncology 24, No. 18S (June 20 Supplement):7522, 2006. e-Pub 2006.
123. Thomas S, Giralt S, Wang M, Delasalle K, Gavino M, Rankin K, Alexanian R, Weber D. Survival Outcomes of Patients Receiving Thalidomide-Dexamethasone for Previously Untreated Multiple Myeloma. Blood:page 1019a, 2006. e-Pub 2006.
124. Stadtmauer E, Weber D, Dimopoulos M, Borello I, San-Miguel J, Hellmann A, Olesnyckyj M, Yu Z, Zeldis B, Knight R. Lenalidomide (Len) in Combination with Dexamethasone (Dex) is More Effective than Dex Alone at First Relapse and Provides Better Outcomes When Used Early Rather than as Later Salvage Therapy in Relpsed Multiple Myeloma (MM). Journal of Clinical Oncology 24(18s), 2006. e-Pub 2006.
125. Chanan-Khan A, Weber D, Dimopoulos M, Chen C, Niesvizky R, Wang M, Belch A, Attal M, Spencer A, Prince M, Olesnycky M, Zeldis J, Yu Z, Knight R. Lenalidomide (L) in Combination with Dexamethasone (D) Improves Survival and Time to Progression in Elderly Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM). Blood:1012a, 2006. e-Pub 2006.
126. Qazibash M, Saliba R, Davis M, Mendoza F, Hosing C, Couriel D, De Lima M, Debriaei S, Weber D, Wang M, Alousi A, Matthes S, Jones R, Champlin R, Giralt S. Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Blood:881a, 2006. e-Pub 2006.
127. Hosing, C, Kebriaei, P, Weber, D, Wang, M, Jones, R, Matthes, S, Champlin, R, Giralt, S. Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan: A New Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Blood 106:1159, 2005. e-Pub 2005.
128. Donato, M, Aleman, A, Weber, D, Wang, M, Qazilbasch, M, Davis, M, Roden, L, Mendoza, F, Champlin, R, Giralt, S. Transplant Outcomes after Topotecan-Melphalan-Cyclophosphamide (TMC) Conditioning for Autologous Stem Cell Transplantation for Multiple Myeloma. Comparison to Melphalan 200mg/m2 (MEL200). Blood 106, 2005. e-Pub 2005.
129. Wang M, Talpaz M, Jagannath S, Chanan-Khan A, Alexanian R, Weber D, Gavino M, Estrov Z, Harris P, Picker D, Schlossman R, Tassone P, Anderson K, Munshi N. A phase I, multicenter dose escalation study of atiprimod in patients with refractory or relapsed multiple myeloma. Blood Abstract 111:36a, 2005. e-Pub 2005.
130. Christoforidou A, Williams P, Roden L, Aleman A, Weber D, Mendoza F, Podoloff D, Breitz H, Alexanian R, Champlin R, Giralt S. Impact of holmium-DOTMP on transplant outcomes for multiple myeloma. Blood, 2005. e-Pub 2005.
131. Weber, DM, Chen C, Niesvizkyr. Multi-Center, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study of Lenalidomide plus Dexamethasone versus dexamethasone alone in previously treated subjects with multiple myeloma. Haematologica 90((51) Abstract PO. 738):155, 2005. e-Pub 2005.
132. Weber D. Lenalidomide (CC-5013, Revlimid) and other IMiDs. . Haematologica 90(51, Abstract PL5.02):24-25, 2005. e-Pub 2005.
133. Wang, M, Alexanian R, Delasalle KB, Weber DM. Confirmation of the Prognostic Value of the International Staging System for Multiple Myeloma proposed by the International Myeloma Working Group and Southwest Oncology Group Staging System using B2microglobulin alone. Haematologica 90(Abstract pO. 308):97, 2005. e-Pub 2005.
134. Giralt S, Aleman A, Lei X, Davis M, Mickler K, Weber D, Wang M, Champlin R. Results of bortezomib (BTZ) Therapy for Myeloma (MM) Patients Relapsing after an Allogeneic Transplant. Preliminary Results Show Efficacy without Induction of GVHD. Blood 104, 2004. e-Pub 2004.
135. Weber, DM, Wang LM, Delasalle KB, Smith T, RAlexanian. Prognostic features of asymptomatic multiple myeloma. International Multiple Myeloma Conference:71-72, 2004. e-Pub 2004.
136. Alexanian, R, DWeber, MWang, KDelasalle. Thalidomide-Dexamethasone as primary treatment for multiple myeloma, and role of added Bortezomib. International Multiple Myeloma Conference:164-5, 2004. e-Pub 2004.
137. Moulopoulos, L, Gika D, Delasalle K, Weber D, Anagnostopoulos M, Alexanian R. Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma. American Society of Hematology (Blood)(Abstract 1485):415a, 2004. e-Pub 2004.
138. Alexanian, R, Wang L, Weber D, Delasalle K. Velcade, thalidomide, dexamethasone as primary therapy for newly-diagnosed multiple myeloma. American Society of Hematology (Blood)(Abstract 210):64a, 2004. e-Pub 2004.
139. Weber, D, Wang M, Delasalle K, Gavino M, Alexanian R. 2-chlorodeoxyadenosine and cyclophosphamide alone, or in combination with rituximab, for previously untreated Waldenstrom’s macroglobulinemia. American Society of Hematology (Blood)(Abstract 1476):413a, 2004. e-Pub 2004.
140. Weber, D, Wang M, Delasalle K, Alexanian R. Confirmation of prognostic value of model using B2M alone. American Society of Hematology (Blood)(Abstract 3491):937a, 2003. e-Pub 2003.
141. Wang, M, Alexanian R, Delasalle K, Weber D. Abnormal MRI of spine is the dominant risk factor for early progression of asymptomatic multiple myeloma. American Society of Hematology (Blood(Abstract 2546):687a, 2003. e-Pub 2003.
142. Alexanian, R, Weber D, Anagnostopoulos A, Delasalle K, Wang M, Rankin K. Thalidomide alone or with dexamethasone for resistant or relapsing multiple myeloma. The Hematology Journal 4:S2, 2003. e-Pub 2003.
143. Alexanian, R, Weber D, Delasalle K, Wang M, Giralt S, Champlin R. Frequency and impact of complete remission with intensive therapy for multiple myeloma. The Hematology Journal(V4 (S1)):S245(352), 2003. e-Pub 2003.
144. Alexanian, R, Weber D, Delasalle K, Wang M, Champlin R, Giralt S. Progressively reduced sensitivity of multiple myeloma to serial intensive therapies. American Society of Hematology (Blood)(Abstract 3654):982a, 2003. e-Pub 2003.
145. Weber, D, Treon SP, Emmanoulides C. Uniform response criteria in waldenstrom’s macroglobulinemia. Consensus panel IV recommendations from the second international workshop on waldenstrom’s macroglobulinemia, The Hematology Journal 4:S1, 2003. e-Pub 2003.
146. Wang, M, Weber D, Delasalle K, Rankin K, Gavino M, Alexanian R. Thalidomide-dexamethasone as primary therapy for multiple myeloma of high tumor mass. The Hematology Journal 4(S1):S245 (352), 2003. e-Pub 2003.
147. Weber, D, Ginsberg C, Walker P, Aholendt M, Rankin K, Gavino M, Delasalle K, Alexanian R. Correlation of Thrombotic/Embolic Events with Features of Hypercoagulability in Previously Untreated Patients before and after Treatment with Thalidomide or Thalidomide-dexamethasone. American Society of Hematology (Blood:209a, 2002. e-Pub 2002.
148. Alexanian, R, Weber D, Delasalle K, Giralt S, Champlin R. Value of Intensive Therapy Supported by Autologous Stem Cells for Primary Resistant Multiple Myeloma. American Society of Hematology (Blood)(Abstract 672):180a, 2002. e-Pub 2002.
149. Alexanian, R, Weber D, Delasalle K, Cabanillas F, Dimopoulos M. Cabanillas F, Dimopoulos M. Asymptomatic Waldenstrom’s disease. American Society of Hematology (Blood)(Abstract 2377):604a, 2002. e-Pub 2002.
150. Weber, D, Albitar M, Delasalle K, Dey A, Rankin K, Gavino M, Walker P, Alexanian R. Correlation of peripheral blood plasma levels of angiogenesis factors with treatment of thalidomide or thalidomide dexamethasone in previously untreated patients with multiple myeloma. American Society of Hematology, Blood(Abstract 3193):808a, 2002. e-Pub 2002.
151. Wang, M, Weber D, Fourney D, Burton A, Schomer D, Ahrar K, Gokaslan Z, Alexanian R. Value of vertobroplasty and kyphoplasty for painful verletual compressions in multiple myeloma. American Society of Hematology (Blood)(Abstract 1565):403a, 2002. e-Pub 2002.
152. Weber, D, Dimopoulos M, Rankin K, Gavino M, Delasalle K, Cabanillas F, Alexanian R. A decade of experience: Primary treatment of Waldenstrom’s macroglobulinemia with 2-chlorodeoxyadenosine alone or in combination. American Society of Hematology (Blood):635a, 2001. e-Pub 2001.
153. Alexanian R, Weber D, Giralt S, Delasalle K. Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. American Society of Hematology (Blood) Abst 686:163a, 2001. e-Pub 2001.
154. Giralt, S, Champlin R, Alexanian R. Results of a Phase I/II trial with 166 Ho-DOTMP plus high dose chemotherapy in patients with multiple myeloma. VIII International Myeloma Workshop(Abst S 24):40-41, 2001. e-Pub 2001.
155. Alexanian, R, Weber D, Delasalle K, Giralt S, Champlin R. Frequency and impact of complete remission in patients with multiple myeloma of low tumor mass who received intensive therapy supported by autologous stem cell transplantation. American Journal of Hematology (Blood)(Abst. 3530):850a, 2001. e-Pub 2001.
156. Anagnostopoulos, A, Aleman A, Williams P, Weber D, Donato M, Alexanian R, Champlin R, Giralt S. Autologous stem cell transplantation after nonmyelosuppressive induction therapy with dexamethasone alone is safe and effective for newly diagnosed multiple myeloma patients who receive high dose chemotherapy. American Society of Hematology (Blood)(Abst. 2858):683a, 2001. e-Pub 2001.
157. Rankin, K, Delasalle K, Gavino M, Alexanian R, Weber D. Progressive decline of myeloma patients referred with advanced disease. VIII International Myeloma Workshop(Abst P106):169, 2001. e-Pub 2001.
158. Wilder, R, Ha C, Cox J, Weber D, Delasalle K, Alexanian R. Persistence of myeloma protein for more than 1 year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone. American Journal of Hematology (Blood)(Abst 3524):849a, 2001. e-Pub 2001.
159. Weber, D, Rankin K, Delasalle I, Gavino M, Alexanian R. Thalidomide alone and in combination for previously untreated myeloma. . VIII International Myeloma Workshop(Abst S 66):109-110, 2001. e-Pub 2001.
160. Delasalle, K, Gavino M, Rankin K, Weber D, Alexanian R. Short survival of older myeloma patients has not improved for 25 years. VIII International Myeloma Workshop(Abst P105):169, 2001. e-Pub 2001.
161. Weber, D, Dimopoulos M, Gavino M, Delasalle K, Rankin K, Alexanian R. Nucleoside analogues: new combinations for treatment of Waldenstrom’s macroglobulinemia. 1st International Symposium on Waldenstrom’s Macroglobulinemia,:10, 2000. e-Pub 2000.
162. Donato, M, Champlin R, Weber D, Alexanian R, Ippoliti C, Aleman A, Cooke S, Martin T, De Lima M, Giralt S. High-dose topotecan, melphalan and cyclophosphamide in multiple myeloma. American Society of Hematology (Blood)(Abst 3446):798a, 2000. e-Pub 2000.
163. Weber, DM, Wang LM, Delasalle KB, Smith T, Alexanian R. Risk factors for early progression asymptomatic multiple myeloma. The Hematology Journal 4(S1):S31, 2000. e-Pub 2000.
164. Weber, D, Rankin K, Gavino M, Delasalle K, Aguayo A, Albitar M, Alexanian R. Angiogenesis factors and sensitivity to thalidomide in previously untreated multiple myeloma. American Society of Hematology (Blood)(Abst 724):168a, 2000. e-Pub 2000.
165. Weber, D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide with dexamethasone for resistant multiple myeloma. American Society of Hematology (Blood)(Abst 719):167a, 2000. e-Pub 2000.
166. Donato, MChu D, Alexanian R, Weber D, Korbling M, Giralt S, Champlin R. Filgrastim alone versus chemotherapy plus filgrastim for peripheral blood stem cell mobilization in multiple myeloma. American Society of Hematology (Blood)(Abst 783):182a, 2000. e-Pub 2000.
167. Giralt, S, Bensinger W, Wendt R, Williams P, Alexanian R, Weber D, Bryan J, Thoelke K, Ha C, McCullough S, Champlin R. Hemorrhagic cystitis after targeted radiotherapy with 166 Holmium-DOTMP for multiple myeloma is preventable with bladder irrigation. American Society of Hematology (Blood)(Abst 1686):391a, 2000. e-Pub 2000.
168. Dang M, Qin L, Tan W, Dong L, Lee HC, Patel KK, Moreno Ruedo LY, Lin P, Bansal H, Berrios D, Thomas SK, Weber DM, Symer DE, Wang L, Manasanch EE, Orlowski RZ. Single cell profiling of BCMA naïve vs refractory relapsed myeloma patients reveals unique transcriptomic profiles in tumor and microenvironment. Blood 140(Publication number 3169).
169. Dang M, Seif S, Acevedo-Calado MJ, PhD, Wang L, Gabriel B, Lewis LS, Gensini L, Bansal H, Becnel MR, Gaballa MR, Lee HC, Pasvolsky O, Patel KK, Weber DM, Ye J, Orlowski RZ, Thomas SK. Characterization of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Using Single Cell Transcriptomic Analysis. ASH.
170. Becnel M, Ferreri CJ, Feng L, Richards TA, Horowitz SB, Patel N, Gombos DS, Razmandi A, Murga A, Seif S, Youssef G, Murphy K, Kaufman GP, Weber DM, Patel KK, Thomas SK, Manasanch EE, Orlowski RZ, Lee HC. Retrospective, single-center, real-world experience of belantamab mafodotin in relapsed/refractory multiple myeloma. ASCO.
171. Pasvolsky O, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour SA, Saini N, Ramdial JL, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Lenalidomide: Based maintenance after autologous hematopoietic stem cell transplant for patients with high-risk multiple myeloma. ASCO.
172. Manasanch EE, Korde N, Lee HC, Patel KK, Becnel M, Berrios D, Thomas SK, Iyer SP, Mailankody S, Amini B, Lin P, Berkova Z, Weber DM, Feng L, Neelapu SS, Jagannath S, Theobald Hildebrandt MA, Orlowski RZ, Landgren O. ISAMAR: Multicenter phase II single arm trial of isatuximab (ISA) with/without lenalidomide (LEN) in pts with high risk smoldering multiple myeloma (HRSMM). ASCO.
173. Lee HC, Li J, Lin H, Murga AD, Rodriguez GM, Mohamed ME, Henderson J, Rodriguez S, Becnel MR, Weber DM, Iyer SP, Kaufman GP, Thomas SK, Manasanch EE, Patel KK, Noga SJ, Green MR, Orlowski RZ, Haymaker CL. Initial Clinical Results and Immune Correlates of a Phase 2 Study of Daratumumab, Bortezomib, Dexamethasone Followed By a Proteasome Inhibitor in-Class Transition ( iCT) to Daratumumab, Ixazomib, Dexamethasone in Relapsed Refractory Multiple Myeloma. ASH.
174. Pasvolsky O, Ghanem S, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour SA, Saini NY, Lin P, Ramdial J, Nieto Y, Khan HN, Kebriaei P, Lee HC, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Outcomes of Patients with Multiple Myeloma and 1q Gain/Amplification Receiving Autologous Hematopoietic Stem Cell Transplant: The MD Anderson Cancer Center Experience. ASH.
175. Alzahrani K, Pasvolsky O, Wang Z, Milton DR, Tanner MR, Bashir Q, Srour SA, Saini NY, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of Revised International Staging System 2 (R2-ISS) Risk Stratification on Outcomes of Patients with Multiple Myeloma Receiving Autologous Hematopoietic Stem Cell Transplantation. ASH.
176. Dang M, Bansal H, Acevedo-Calado MJ, Qin L, Tan W, Moreno Rueda LYM, Huang M, Nolasco DB, Lee HC, Patel KK, Lin P, Thomas SK, Weber DM, Wang L, Manasanch EE, Orlowski RZ. Single Cell Multi-Omic Analysis of Tumor Microenvironment Evolution across the Disease Spectrum of Multiple Myeloma Identies Differential Mechanisms of Immune Suppression. ASH.
177. Pasvolsky O, Pasyar S, Bassett RL, Khan HN, Tanner MR, Bashir Q, Srour SA, Saini NY, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of Pre-Transplant Minimal Residual Disease in Patients with Multiple Myeloma with ≥ Very Good Partial Response Receiving Autologous Hematopoietic Stem Cell Transplantation. ASH.
178. Moreno Rueda LY, Akagi K, Vora AU, Lee HC, Patel KK, Lin P, Jiang B, Song Y, Gillison ML, Thomas SK, Weber DM, Diao L, Wang J, Manasanch EE, Symer DE, Orlowski RZ. 651.Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational| November 2, 2023 Single Cell Multi-Omic Analysis of Neoplastic Plasma Cells across the Disease Spectrum Identifies Novel Pathobiologic Mediators and Potential Therapeutic Targets in Multiple Myeloma (MM). ASH.
179. Pasvolsky O, Hildebrandt M, Subramanian N, Ferreri C, Lee HC, Manasanch EE, Thomas SK, Weber DM, Gaballa M, Dillard C, Becnel M, Hosing C, Lin P, Amini B, Qazilbash MH, Kalariya N, Orlowski RZ, Patel KK. Safety and Efcacy Outcomes for Patients with High-Risk Multiple Myeloma Receiving Idecabtagene Vicleucel: The MD Anderson Experienc. ASH.
180. Wang H, Moreno Rueda LY, Dang M, Moreno Rueda LY, Lee HC, Patel KK, Thomas SK, Weber DM, Manasanch EE, Symer DE, Orlowski RZ. Lysosomal Associated Membrane Protein Family Member 5 (LAMP5) As a Novel Mediator of, and Target in High Risk Multiple Myeloma (MM). ASH.
181. Subramanian N, Gurumurthi A, Pasvolsky O, Ferreri C, Lee HC, Manasanch EE, Thomas SK, Weber DM, Gaballa M, Dillard C, Becnel M, Hosing C, Lin P, Amini B, Qazilbash MH, Kalariya N, Hawkins M, Ahmed S, Orlowski RZ, Patel KK. Attrition after Referral for Chimeric Antigen Receptor T-Cell (CAR-T) Products in Multiple Myeloma (MM). ASH.
182. Pasvolsky O, Marcoux C, Dai J, Milton DR, Tanner MR, Syed N, Bashir Q, Srour SA, Saini NY, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Trends in Outcomes over Three Decades after Upfront Autologous Stem Cell Transplant for Multiple Myeloma at MD Anderson Cancer Center. ASH.
183. Pasvolsky O, Patel KK, Bashir Q, Rauf M, Sui D, Srour SA, Tanner MR, Popat UR, Saini NY, Hosing C, Ramdial J, Manasanch EE, Lee HC, Kaufman GP, Thomas SK, Weber DM, Becnel MR, Tang G, Orlowski RZ, Patel D, Champlin RE, Nieto Y, Shpall EJ, Qazilbash MH. Daratumumab-Based Maintenance in Patients with Relapsed Multiple Myeloma after Salvage Autologous Hematopoietic Stem Cell Transplantation. ASH.
184. Thomas SK, George JS, de Partovi CMM, Feng L, Morphey AS, Becnel MR, Kaufman GP, Lee HC, Manasanch EE, Patel KK, Pasvolsky O, Ye JC, Amini B, Qazilbash MH, Bashir Q, Crumpton BN, Stafford MM, Ralph J Johnson III, Weber DM, Orlowski RZ. Final results of a phase II study of lenalidomide-elotuzumab as maintenance therapy post-autologous stem cell transplant (AuSCT) in patients (Pts) with multiple myeloma (MM). ASCO.
185. Dang M, Lee HC, Bansal H, Acevedo-Calado M, Qin L, Tan W, Moreno Rueda LY, Berrios D, Patel KK, Lin P, Thomas SK, Weber DM, Wang L, Orlowski RZ. Single-Cell Multi-Omic Profiling of Patients with BCMA-Targeted Therapy Identifies Molecular and Cellular Factors Associated with Responsiveness and Treatment Effects. ASH.
186. Dillard CM, Gurumurthi A, Lee HC, Thomas SK, Weber DM, Orlowski RZ, Qazilbash MH, Patel KK, Hildebrandt MA. Association of Social Determinants of Health Status (SDOH) and Ethnicity with Survival in Multiple Myeloma Patients. ASH.
187. Patel KK, Manasanch EE, Lee HC, Ye J, Thomas SK, Weber DM, Becnel MR, Gaballa MR, Bansal H, Berkova Z, Neelapu SS, Haymaker CL, Dang M, Wang, L, Lizee G, Orlowski RZ. Personalized Neoantigen Peptide Vaccine with or without Lenalidomide for Patients with Intermediate or High Risk Smoldering Multiple Myeloma (SMM) to Prevent Progression to Multiple Myeloma (MM). ASH.
188. Sami SS, Bashir Q, Saini NY, Aljawai YM, Hosing C, Popat U, Becnel MR, Kaufman GP, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH, Srour SA. Impact of Age on Autologous Stem Cell Transplantation Outcomes for AL Amyloidosis. ASH.
189. Dang M, Lee HC, Bansal H, Acevedo-Calado MJ, Qin L, Tan W, Moreno Rueda LY, Berrios D, Pasvolsky O, Gaballa MR, Becnel MR, Ye J, Patel KK, Lin P, Thomas SK, Weber DM, Wang L, Orlowski RZ. Multi-Omic Single-Cell Characterization of Paired and Serial Samples in Responding and Non-Responding Patients Receiving BCMA Bispecific Antibody Therapy for Multiple Myeloma. ASH.
190. Deen AF, Bashir Q, Saini NY, Aljawai YM, Hosing C, Popat U, Becnel MR, Kaufman GP, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Srour SA. Predictive Factors for Transplant Outcomes of Cardiac AL Amyloidosis. ASH.
191. Dhakal B, Slade M, Narra R, Mohamed ME, Akhtar OS, Bansal H, Acevedo-Calado MJ, Pasvolsky O, Gaballa MR, Becnel MR, Weber DM, Patel KK, Thomas SK, Ye J, Kuhr F, Dong B, Powell S, Bui T, Mohan M, Pasquini MC, D'Souza A, Knysh H, Orlowski RZ, Albitar M, Lee HC. Clearance of Circulating Multiple Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma. ASH.
192. Ye J, Tang G, Pasvolsky O, Becnel MR, Gaballa MR, Patel KK, Lee HC, Thomas SK, Weber DM, Pen Li, Orlowski RZ. Unveiling Clinical Potential: Exploring Cytogenomic Aberrations through Optical Genomic Mapping in Multiple Myeloma. ASH.
193. Lionel A, Seif S, Sun X, Feng L, Gensini L, Gabriel B, Lewis LS, Bansal H, Becnel MR, Gaballa MR, Lee HC, Pasvolsky O, Patel KK, Ye J, Patel KP, Weber DM, Orlowski RZ, Thomas SK. Prognostic Significance of TP53 Mutations in Lymphoplasmacytic Lymphoma. ASH.

Book Chapters

1. Haygood T, Marom E, Weber DM. Myeloma and Leukemia. In: Oncologic Imaging: A Multidisiplinary Approach, 509-530, 2012.
2. Thomas S, Richards T, Weber D. Lenalidoide: relapsed disease. In lonial S (ed). In: Contemporary Hematology: Myeloma Therapy: Pursuing the Plasma Cell. Humana Press, 265-278, 2008.
3. Thomas S, Richards T, Weber D. Novel Agents for Previously Untreated Multiple Myeloma. In: Multiple Myeloma: Translational and Emerging Therapies. Ghobrial I and Anderson K (Ed). Informa healthcare. Informa Healthcare, 141-167, 2007.
4. Seymour G, Wang M, Lin P, Weber D. Multiple Myeloma and Other Plasma Cell Dyscrasias in Kantarjian HM. In: MD Anderson Manual of Medical Oncology, 175-193, 2006.
5. Donna W. Thalidomide treatment. In: Multiple Myeloma, 79-83, 2004.
6. Weber D. Multiple Myeloma Guidelines. In: Color Matrix Cancer staging and treatment handbook, 3rd ed.,, 45, 130, 2000.
7. Weber DM. Multiple myeloma and plasma cell dyscrasias. In: Cancer Management: A Multidisciplinary Approach. PRR Publications (in press), 2000.
8. Waxman, ES, Weber DM. Multiple myeloma and other plasma cell dyscrasias. In: Primary Care Oncology, 339-352, 1999.
9. Weber DM. Multiple Myeloma and Other Plasma Cell Dyscrasias. In: MKSAP in the subspecialty of hematology, 1999.
10. DM: W. Multiple myeloma and plasma cell dyscrasias . In: Cancer Management: A multidisciplinary approach, 1999.
11. Buzaid, AC, Weber DM. Abnormal serum protein electrophoresis. In: Decision making in medicine an algorithmic approah , (ed.2), 236-239, 1998.
12. Papadimitrakopoulou, V, Weber DM. Multiple myeloma and other plasma cell dyscrasias. In: Medical Oncology: A Comprehensive Review, 127-135, 1996.
13. Alexanian, R, Dimopoulos M, Weber D, Delasalle K, Hester J, Champlin R. Intensive sequential therapy for VAD-resistant multiple myeloma. Multiple Myeloma and Related Disorders. In: Challenges of Modern Medicine. Ares-Serona Symposia Publications, 175-182, 1994.
14. Weber, DM, Alexanian R. Multiple myeloma and other plasma cell dyscrasias. In: Medical Oncology: A Comprehensive Review, 49-58, 1993.

Books (edited and written)

1. Richards T, Weber D. Advances in treatment for relapses and refractory multiple myeloma, 2010.

Letters to the Editor

1. Chohan, KL, Gensini, L, Seif, S, Sun, X, Feng, L, Becnel, M, Gaballa, MM, Lee, HC, Pasvolsky, O, Patel, K, Ye, JC, Weber, DM, Orlowski, R, Thomas, SK. Long-term outcomes and treatment patterns in Waldenström macroglobulinemia patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy. Blood cancer journal 15, 2025.
2. Weber, DM, Pugh WC, Steinbach G. Cure of gastric lymphoma with antibiotics. Gastroenterology 109: 334-335, 1995.
3. Weber, DM, Daliani D, Alexanian R. Clinical Problem Solving: costly errors. N Engl J. Med 333: 1080, 1995.
4. Weber, DM, Dimopoulos MA, Alexanian R. Increased neurotoxicity with VAD-cyclosporin in mutliple myeloma. Lancet 341: 558-9, 1993.
5. Dimopoulos, MA, Weber DM, Estey EE, Alexanian R. Primary treatment with 2-Chlorodeoxyadenosine of low grade lymphomas that produce IgG or IgA immunoglobulin. Am J Hematol: 326-27, 1993.